The	O
hypotensive	B-Disease
effect	O
of	O
100	O
mg	O
/	O
kg	O
alpha-methyldopa	B-Chemical
was	O
also	O
partially	O
reversed	O
by	O
naloxone	B-Chemical
.	O

Naloxone	B-Chemical
alone	O
did	O
not	O
affect	O
either	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O

Lidocaine	B-Chemical
-	O
induced	O
cardiac	B-Disease
asystole	I-Disease
.	O

The	O
patient	O
had	O
no	O
apparent	O
associated	O
conditions	O
which	O
might	O
have	O
predisposed	O
him	O
to	O
the	O
development	O
of	O
bradyarrhythmias	B-Disease
;	O
and	O
,	O
thus	O
,	O
this	O
probably	O
represented	O
a	O
true	O
idiosyncrasy	O
to	O
lidocaine	B-Chemical

Suxamethonium	B-Chemical
chloride	I-Chemical
(	O
Sch	B-Chemical
)	O
was	O
administered	O
i	O
.	O

The	O
infusion	O
was	O
discontinued	O
either	O
when	O
there	O
was	O
no	O
muscular	O
response	O
to	O
tetanic	B-Disease
stimulation	O
of	O
the	O
ulnar	O
nerve	O
or	O
when	O
Sch	B-Chemical
120	O
mg	O
was	O
exceeded	O
.	O

Fasciculations	B-Disease
in	O
six	O
areas	O
of	O
the	O
body	O
were	O
scored	O
from	O
0	O
to	O
3	O
and	O
summated	O
as	O
a	O
total	O
fasciculation	B-Disease
score	O
.	O

Fasciculations	B-Disease
in	O
the	O
six	O
areas	O
and	O
the	O
total	O
fasciculation	B-Disease
score	O
were	O
related	O
directly	O
to	O
the	O
rate	O
of	O
infusion	O
.	O

However	O
,	O
studies	O
into	O
the	O
dose	O
necessary	O
to	O
combating	O
scopolamine	B-Chemical

Effects	O
of	O
uninephrectomy	O
and	O
high	O
protein	O
feeding	O
on	O
lithium	B-Chemical
-	O
induced	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
in	O
rats	O
.	O

Corresponding	O
non	O
-	O
lithium	B-Chemical
pretreated	O
groups	O
were	O
generated	O
.	O

Consequently	O
,	O
lithium	B-Chemical
pretreatment	O
caused	O
a	O
fall	O
in	O
filtration	O
fraction	O
and	O
an	O
increase	O
in	O
fractional	O
Li	B-Chemical
excretion	O
.	O

Lithium	B-Chemical
also	O
caused	O
proteinuria	B-Disease
and	O
systolic	O
hypertension	B-Disease
in	O
absence	O
of	O
glomerulosclerosis	B-Disease
.	O

The	O
results	O
indicate	O
that	O
Li	B-Chemical
-	O
induced	O
nephropathy	B-Disease
,	O
even	O
when	O
the	O
GFR	O
is	O
only	O
modestly	O
reduced	O
,	O
is	O
associated	O
with	O
proteinuria	B-Disease
and	O
arterial	O
systolic	O
hypertension	B-Disease
.	O

In	O
this	O
model	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease

Fusidic	O
acid	O
is	O
an	O
antibiotic	O
with	O
T	O
-	O
cell	O
specific	O
immunosuppressive	O
effects	O
similar	O
to	O
those	O
of	O
cyclosporin	B-Chemical
.	O

Because	O
of	O
the	O
need	O
for	O
the	O
development	O
of	O
new	O
treatments	O
for	O
Crohn's	B-Disease
disease	I-Disease
,	O
a	O
pilot	O
study	O
was	O
undertaken	O
to	O
estimate	O
the	O
pharmacodynamics	O
and	O
tolerability	O
of	O
fusidic	B-Chemical
acid	I-Chemical
treatment	O
in	O
chronic	O
active	O
,	O
therapy	O
-	O
resistant	O
patients	O
.	O

Five	O
of	O
8	O
patients	O
(	O
63	O
%)	O
improved	O
during	O
fusidic	B-Chemical
acid	I-Chemical
treatment	O
:	O
3	O
at	O
two	O
weeks	O
and	O
2	O
after	O
four	O
weeks	O
.	O

There	O
were	O
no	O
serious	O
clinical	O
side	O
effects	O
,	O
but	O
dose	O
reduction	O
was	O
required	O
in	O
two	O
patients	O
because	O
of	O
nausea	B-Disease
.	O

Because	O
there	O
seems	O
to	O
exist	O
a	O
scientific	O
rationale	O
for	O
the	O
use	O
of	O
fusidic	B-Chemical
acid	I-Chemical
at	O
the	O
cytokine	O
level	O
in	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease

The	O
electrocardiograms	O
(	O
ECG	O
)	O
of	O
99	O
cocaine	B-Chemical
-	O
abusing	O
patients	O
were	O
compared	O
with	O
the	O
ECGs	O
of	O
50	O
schizophrenic	B-Disease
controls	O
.	O

Sulpiride	B-Chemical
-	O
induced	O
tardive	B-Disease
dystonia	I-Disease
.	O

We	O
studied	O
a	O
37	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
persistent	O
segmental	O
dystonia	B-Disease
within	O
2	O
months	O
after	O
starting	O
sulpiride	B-Chemical
therapy	O
.	O

Ocular	B-Disease
and	I-Disease
auditory	I-Disease
toxicity	I-Disease
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	B-Chemical
.	O

Visual	B-Disease
toxicity	I-Disease
was	O
of	O
retinal	O
origin	O
and	O
was	O
characterized	O
by	O
a	O
tritan	O
-	O
type	O
dyschromatopsy	B-Disease
,	O
sometimes	O
associated	O
with	O
a	B-Disease
loss	I-Disease
of	I-Disease
visual	I-Disease
acuity	I-Disease
and	O
pigmentary	B-Disease
retinal	I-Disease
deposits	I-Disease
.	O

Desferrioxamine	B-Chemical
withdrawal	O
resulted	O
in	O
a	O
complete	O
recovery	O
of	O
visual	O
function	O
in	O
1	O
patient	O
and	O
partial	O
recovery	O
in	O
3	O
,	O
and	O
a	O
complete	O
reversal	O
of	O
hearing	B-Disease
loss	I-Disease
in	O
3	O
patients	O
and	O
partial	O
recovery	O
in	O
3	O
.	O

The	O
data	O
indicate	O
that	O
audiovisual	B-Disease
toxicity	I-Disease
is	O
not	O
an	O
infrequent	O
complication	O
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	B-Chemical

We	O
studied	O
a	O
patient	O
with	O
no	O
prior	O
history	O
of	O
neuromuscular	B-Disease
disease	I-Disease
who	O
became	O
virtually	O
quadriplegic	B-Disease
after	O
parenteral	O
magnesium	B-Chemical
administration	O
for	O
preeclampsia	B-Disease
.	O

The	O
serum	O
magnesium	B-Chemical
concentration	O
was	O
3	O
.	O

While	O
she	O
was	O
weak	O
,	O
2	O
-	O
Hz	O
repetitive	O
stimulation	O
revealed	O
a	O
decrement	O
without	O
significant	O
facilitation	O
at	O
rapid	O
rates	O
or	O
after	O
exercise	O
,	O
suggesting	O
postsynaptic	B-Disease
neuromuscular	I-Disease
blockade	I-Disease
.	O

Her	O
acetylcholine	B-Chemical
receptor	O
antibody	O
level	O
was	O
markedly	O
elevated	O
.	O

Patients	O
who	O
are	O
unusually	O
sensitive	O
to	O
the	O
neuromuscular	O
effects	O
of	O
magnesium	B-Chemical
should	O
be	O
suspected	O
of	O
having	O
an	O
underlying	O
disorder	B-Disease
of	I-Disease
neuromuscular	I-Disease
transmission	I-Disease

The	O
data	O
demonstrate	O
that	O
CAA	B-Chemical
after	O
i	O
.	O

Source	O
of	O
pain	B-Disease
and	O
primitive	O
dysfunction	O
in	O
migraine	B-Disease
:	O
an	O
identical	O
site	O
?	O
Twenty	O
common	O
migraine	B-Disease
patients	O
received	O
a	O
one	O
sided	O
frontotemporal	O
application	O
of	O
nitroglycerin	B-Chemical
(	O
10	O
patients	O
)	O
or	O
placebo	O
ointment	O
(	O
10	O
patients	O
)	O
in	O
a	O
double	O
blind	O
study	O
.	O

Subsequently	O
20	O
migraine	B-Disease
patients	O
,	O
who	O
developed	O
an	O
early	O
onset	O
attack	O
with	O
frontotemporal	O
nitroglycerin	B-Chemical
,	O
received	O
the	O
drug	O
in	O
a	O
second	O
induction	O
test	O
at	O
other	O
body	O
areas	O
.	O

No	O
early	O
onset	O
migraine	B-Disease
was	O
observed	O
.	O

Clotiazepam	B-Chemical
-	O
induced	O
acute	O
hepatitis	B-Disease
.	O

Clotiazepam	B-Chemical
withdrawal	O
was	O
followed	O
by	O
prompt	O
recovery	O
.	O

The	O
administration	O
of	O
several	O
benzodiazepines	B-Chemical
,	O
chemically	O
related	O
to	O
clotiazepam	B-Chemical
,	O
did	O
not	O
interfere	O
with	O
recovery	O
and	O
did	O
not	O
induce	O
any	O
relapse	O
of	O
hepatitis	B-Disease
.	O

Arterial	O
hypertension	B-Disease
as	O
a	O
complication	O
of	O
prolonged	O
ketoconazole	B-Chemical
treatment	O
.	O

In	O
both	O
cases	O
normal	O
plasma	O
and	O
urinary	O
free	O
cortisol	B-Chemical
levels	O
had	O
been	O
achieved	O
following	O
ketoconazole	B-Chemical
therapy	O
,	O
yet	O
continuous	O
blood	O
pressure	O
monitoring	O
demonstrated	O
hypertension	B-Disease
31	O
(	O
patient	O
1	O
)	O
and	O
52	O
weeks	O
(	O
patient	O
2	O
)	O
after	O
treatment	O
.	O

In	O
patient	O
2	O
,	O
in	O
addition	O
to	O
an	O
increase	O
in	O
both	O
deoxycorticosterone	B-Chemical
and	O
11-deoxycortisol	B-Chemical
levels	O
,	O
plasma	O
aldosterone	B-Chemical
values	O
were	O
raised	O
,	O
with	O
a	O
concomitant	O
suppression	O
of	O
renin	O
levels	O
.	O

Effects	O
of	O
an	O
inhibitor	O
of	O
angiotensin	B-Chemical
converting	O
enzyme	O
(	O
Captopril	B-Chemical
)	O
on	O
pulmonary	B-Disease
and	I-Disease
renal	I-Disease
insufficiency	I-Disease
due	O
to	O
intravascular	B-Disease
coagulation	I-Disease
in	O
the	O
rat	O
.	O

Injection	O
of	O
Captopril	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
),	O
an	O
inhibitor	O
of	O
angiotensin	B-Chemical
converting	O
enzyme	O
(	O
ACE	O
),	O
reduced	O
both	O
pulmonary	B-Disease
and	I-Disease
renal	I-Disease
insufficiency	I-Disease
in	O
this	O
rat	O
model	O
.	O

The	O
amount	O
of	O
fibrin	O
in	O
the	O
kidneys	O
was	O
also	O
considerably	O
lower	O
than	O
in	O
animals	O
which	O
received	O
thrombin	O
and	O
AMCA	B-Chemical
alone	O
.	O

It	O
is	O
suggested	O
that	O
the	O
effects	O
of	O
Captopril	B-Chemical
on	O
the	O
lungs	O
may	O
be	O
attributable	O
to	O
a	O
vasodilatory	O
effect	O
due	O
to	O
a	O
reduction	O
in	O
the	O
circulating	O
level	O
of	O
Angiotension	B-Chemical
II	I-Chemical
and	O
an	O
increase	O
in	O
prostacyclin	B-Chemical
(	O
secondary	O
to	O
an	O
increase	O
in	O
bradykinin	B-Chemical
).	O
Captopril	B-Chemical
may	O
,	O
by	O
the	O
same	O
mechanism	O
,	O
reduce	O
the	O
increase	O
in	O
glomerular	O
filtration	O
that	O
is	O
known	O
to	O
occur	O
after	O
an	O
injection	O
of	O
thrombin	O
,	O
thereby	O
diminishing	O
the	O
aggregation	O
of	O
fibrin	O
monomers	O
in	O
the	O
glomeruli	O
,	O
with	O
the	O
result	O
that	O
less	O
fibrin	O
will	O
be	O
deposited	O
and	O
thus	O
less	O
kidney	B-Disease
damage	I-Disease

In	O
a	O
randomized	O
study	O
,	O
labetalol	B-Chemical
-	O
induced	O
hypotension	B-Disease
and	O
nitroprusside	B-Chemical
-	O
induced	O
hypotension	B-Disease
were	O
compared	O
in	O
20	O
patients	O
(	O
10	O
in	O
each	O
group	O
)	O
scheduled	O
for	O
major	O
orthopedic	O
procedures	O
.	O

Each	O
patient	O
was	O
subjected	O
to	O
an	O
identical	O
anesthetic	O
protocol	O
and	O
similar	O
drug	O
-	O
induced	O
reductions	B-Disease
in	I-Disease
mean	I-Disease
arterial	I-Disease
blood	I-Disease
pressure	I-Disease
(	O
BP	O
)(	O
50	O
to	O
55	O
mmHg	O
).	O
Nitroprusside	O
infusion	O
was	O
associated	O
with	O
a	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O

Arterial	O
PO2	B-Chemical
decreased	O
in	O
both	O
groups	O
.	O

Chronic	O
carbamazepine	B-Chemical
treatment	O
in	O
the	O
rat	O
:	O
efficacy	O
,	O
toxicity	B-Disease
,	O
and	O
effect	O
on	O
plasma	O
and	O
tissue	O
folate	B-Chemical
concentrations	O
.	O

Folate	B-Chemical
depletion	O
has	O
often	O
been	O
a	O
problem	O
in	O
chronic	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
therapy	O
.	O

A	O
rat	O
model	O
was	O
developed	O
to	O
examine	O
the	O
effects	O
of	O
chronic	O
CBZ	B-Chemical
treatment	O
on	O
folate	B-Chemical
concentrations	O
in	O
the	O
rat	O
.	O

Seizures	B-Disease
induced	O
by	O
hexafluorodiethyl	B-Chemical
ether	I-Chemical
(	O
HFDE	B-Chemical
)	O
were	O
also	O
found	O
to	O
be	O
a	O
more	O
sensitive	O
measure	O
of	O
protection	O
by	O
CBZ	B-Chemical
than	O
seizures	B-Disease
induced	O
by	O
maximal	O
electroshock	O
(	O
MES	O
).	O
Oral	O
administration	O
of	O
CBZ	B-Chemical
as	O
an	O
aqueous	O
suspension	O
every	O
8	O
h	O
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
was	O
continuously	O
protective	O
against	O
HFDE	B-Chemical
-	O
induced	O
seizures	B-Disease
and	O
was	O
minimally	O
toxic	O
as	O
measured	O
by	O
weight	B-Disease
gain	I-Disease
over	O
8	O
weeks	O
of	O
treatment	O
.	O

This	O
treatment	O
with	O
CBZ	B-Chemical
had	O
no	O
apparent	O
adverse	O
effect	O
on	O
folate	B-Chemical
concentrations	O
in	O
the	O
rat	O
,	O
and	O
,	O
indeed	O
,	O
the	O
folate	B-Chemical

3	O
microgram	O
/	O
kg	O
/	O
min	O
)	O
were	O
observed	O
,	O
which	O
is	O
in	O
contrast	O
to	O
comparable	O
hypotension	B-Disease
induced	O
by	O
hydralazine	B-Chemical
or	O
nitroglycerin	B-Chemical
.	O

The	O
release	O
rate	O
of	O
epinephrine	B-Chemical

Multiple	O
cytotoxic	O
drug	O
administration	O
is	O
the	O
generally	O
accepted	O
treatment	O
of	O
patients	O
with	O
a	O
high	O
-	O
risk	O
stage	O
of	O
choriocarcinoma	B-Disease
.	O

213	O
,	O
Methotrexate	B-Chemical
,	O
Cyclophosphamide	B-Chemical
,	O
Actomycin-D	B-Chemical
,	O
and	O
Cisplatin	B-Chemical
.	O

Formation	O
of	O
these	O
plugs	O
was	O
probably	O
due	O
to	O
extensive	O
tumor	B-Disease
necrosis	B-Disease
at	O
the	O
level	O
of	O
the	O
walls	O
of	O
the	O
major	O
uterine	O
veins	O
,	O
which	O
resulted	O
in	O
an	O
open	O
exchange	O
of	O
tumor	B-Disease
plugs	O
to	O
the	O
vascular	O
spaces	O
;	O
decrease	O
in	O
tumor	B-Disease
tissue	O
coherence	O
secondary	O
to	O
chemotherapy	O
may	O
have	O
further	O
contributed	O
to	O
the	O
formation	O
of	O
tumor	B-Disease
emboli	O
.	O

Patients	O
with	O
large	O
pelvic	B-Disease
tumor	I-Disease

The	O
relationship	O
of	O
arthritis	B-Disease
and	O
sexual	B-Disease
dysfunction	I-Disease
was	O
investigated	O
among	O
169	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
,	O
osteoarthritis	B-Disease
and	O
spondyloarthropathy	B-Disease
,	O
130	O
of	O
whom	O
were	O
pair	O
-	O
matched	O
to	O
controls	O
.	O

Depressed	B-Disease
mood	I-Disease
was	O
more	O
common	O
among	O
patients	O
and	O
was	O
associated	O
with	O
certain	O
sexual	O
difficulties	O
,	O
but	O
not	O
with	O
impotence	B-Disease
.	O

Does	O
paracetamol	B-Chemical
cause	O
urothelial	B-Disease
cancer	I-Disease
or	O
renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
?	O
The	O
risk	O
of	O
developing	O
renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
or	O
cancer	B-Disease
of	I-Disease
the	I-Disease
renal	I-Disease
pelvis,	I-Disease
ureter	I-Disease
or	I-Disease
bladder	I-Disease
associated	O
with	O
consumption	O
of	O
either	O
phenacetin	B-Chemical
or	O
paracetamol	B-Chemical
was	O
calculated	O
from	O
data	O
acquired	O
by	O
questionnaire	O
from	O
381	O
cases	O
and	O
808	O
controls	O
.	O

By	O
contrast	O
,	O
we	O
were	O
unable	O
to	O
substantiate	O
an	O
increased	O
risk	O
from	O
paracetamol	B-Chemical
consumption	O
for	O
renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
or	O
any	O
of	O
these	O
cancers	B-Disease
although	O
there	O
was	O
a	O
suggestion	O
of	O
an	O
association	O
with	O
cancer	B-Disease
of	I-Disease
the	I-Disease
ureter	I-Disease

A	O
Cambodian	O
woman	O
with	O
hemoglobin	O
E	O
trait	O
(	O
AE	O
)	O
and	O
leprosy	B-Disease
developed	O
a	O
Heinz	O
body	O
hemolytic	B-Disease
anemia	I-Disease
while	O
taking	O
a	O
dose	O
of	O
dapsone	B-Chemical
(	O
50	O
mg	O
/	O
day	O
)	O
not	O
usually	O
associated	O
with	O
clinical	O
hemolysis	B-Disease
.	O

Her	O
red	O
blood	O
cells	O
(	O
RBCs	O
)	O
had	O
increased	O
incubated	O
Heinz	O
body	O
formation	O
,	O
decreased	O
reduced	O
glutathione	B-Chemical
(	O
GSH	B-Chemical
),	O
and	O
decreased	O
GSH	B-Chemical
stability	O
.	O

Although	O
the	O
AE	O
RBCs	O
from	O
an	O
individual	O
not	O
taking	O
dapsone	B-Chemical
had	O
increased	O
incubated	O
Heinz	O
body	O
formation	O
,	O
the	O
GSH	B-Chemical
content	O
and	O
GSH	B-Chemical
stability	O
were	O
normal	O
.	O

Given	O
the	O
influx	O
of	O
Southeast	O
Asians	O
into	O
the	O
United	O
States	O
,	O
oxidant	O
medications	O
should	O
be	O
used	O
with	O
caution	O
,	O
especially	O
if	O
an	O
infection	B-Disease

Severe	O
complications	O
of	O
antianginal	O
drug	O
therapy	O
in	O
a	O
patient	O
identified	O
as	O
a	O
poor	O
metabolizer	O
of	O
metoprolol	B-Chemical
,	O
propafenone	B-Chemical
,	O
diltiazem	B-Chemical
,	O
and	O
sparteine	B-Chemical
.	O

AV	B-Disease
block	I-Disease
,	O
severe	O
hypotension	B-Disease
,	O
and	O
impairment	B-Disease
of	I-Disease
ventricular	I-Disease
function	I-Disease
.	O

Two	O
days	O
before	O
admission	O
diltiazem	B-Chemical
(	O
60	O
mg	O
b	O
.	O

Three	O
months	O
later	O
the	O
patient	O
was	O
exposed	O
to	O
a	O
single	O
dose	O
of	O
metoprolol	B-Chemical
,	O
diltiazem	B-Chemical
,	O
propafenone	B-Chemical
(	O
since	O
he	O
had	O
received	O
this	O
drug	O
in	O
the	O
past	O
),	O
and	O
sparteine	B-Chemical
(	O
as	O
a	O
probe	O
for	O
the	O
debrisoquine	B-Chemical
/	O
sparteine	B-Chemical
type	O
polymorphism	O
of	O
oxidative	O
drug	O
metabolism	O
).	O
It	O
was	O
found	O
that	O
he	O
was	O
a	O
poor	O
metabolizer	O
of	O
all	O
four	O
drugs	O
,	O
indicating	O
that	O
their	O
metabolism	O
is	O
under	O
the	O
same	O
genetic	O
control	O
.	O

Triazolam	B-Chemical
-	O
induced	O
brief	O
episodes	O
of	O
secondary	O
mania	B-Disease
in	O
a	O
depressed	B-Disease
patient	O
.	O

Features	O
of	O
organic	B-Disease
mental	I-Disease
disorder	I-Disease
(	O
delirium	B-Disease
)	O
were	O
not	O
present	O
.	O

Manic	B-Disease
excitement	O
was	O
coincident	O
with	O
the	O
duration	O
of	O
action	O
of	O
triazolam	B-Chemical
.	O

The	O
possible	O
contribution	O
of	O
the	O
triazolo	B-Chemical

The	O
development	O
of	O
tolerance	O
to	O
the	O
muscular	B-Disease
rigidity	I-Disease
produced	O
by	O
morphine	B-Chemical
was	O
studied	O
in	O
rats	O
.	O

The	O
rigidity	B-Disease
was	O
considerably	O
decreased	O
in	O
both	O
groups	O
after	O
20	O
days	O
'	O
treatment	O
.	O

In	O
a	O
further	O
series	O
of	O
experiments	O
,	O
haloperidol	B-Chemical
(	O
0	O
.	O

Haloperidol	B-Chemical
enhanced	O
the	O
rigidity	B-Disease
in	O
the	O
A	O
group	O
.	O

The	O
rapid	O
alternations	O
of	O
rigidity	B-Disease

Compression	B-Disease
neuropathy	I-Disease
of	I-Disease
the	I-Disease
radial	I-Disease
nerve	I-Disease
due	O
to	O
pentazocine	B-Chemical
-	O
induced	O
fibrous	B-Disease
myopathy	I-Disease
.	O

However	O
,	O
compression	B-Disease
neuropathy	I-Disease
due	O
to	O
fibrotic	O
muscle	O
affected	O
by	O
pentazocine	B-Chemical
-	O
induced	O
myopathy	B-Disease
has	O
not	O
previously	O
been	O
reported	O
.	O

Recurrent	O
reversible	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
from	O
amphotericin	B-Chemical
.	O

We	O
propose	O
that	O
amphotericin	B-Chemical
,	O
in	O
the	O
setting	O
of	O
reduced	O
effective	O
arterial	O
volume	O
,	O
may	O
activate	O
tubuloglomerular	O
feedback	O
,	O
thereby	O
contributing	O
to	O
acute	B-Disease
renal	I-Disease
failure	I-Disease

A	O
patient	O
with	O
sinuatrial	B-Disease
disease	I-Disease
and	O
implanted	O
pacemaker	O
was	O
treated	O
with	O
amiodarone	B-Chemical
(	O
maximum	O
dose	O
1000	O
mg	O
,	O
maintenance	O
dose	O
800	O
mg	O
daily	O
)	O
for	O
10	O
months	O
,	O
for	O
control	O
of	O
supraventricular	B-Disease
tachyarrhythmias	I-Disease
.	O

He	O
developed	O
pneumonitis	B-Disease
,	O
pleural	B-Disease
and	I-Disease
pericardial	I-Disease
effusions	I-Disease
,	O
and	O
a	O
predominantly	O
proximal	B-Disease
motor	I-Disease
neuropathy	I-Disease
.	O

Indomethacin	B-Chemical
-	O
induced	O
renal	B-Disease
insufficiency	I-Disease
:	O
recurrence	O
on	O
rechallenge	O
.	O

Prompt	O
restoration	O
of	O
renal	O
function	O
followed	O
drug	O
withdrawal	O
,	O
while	O
re	O
-	O
exposure	O
to	O
a	O
single	O
dose	O
of	O
indomethacin	B-Chemical
caused	O
recurrence	O
of	O
acute	O
reversible	O
oliguria	B-Disease
.	O

Our	O
case	O
supports	O
the	O
hypothesis	O
that	O
endogenous	O
renal	O
prostaglandins	B-Chemical
play	O
a	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
blood	O
flow	O
when	O
circulating	O
plasma	O
volume	O
is	O
diminished	O
.	O

Flunitrazepam	B-Chemical
0	O
.	O

Dizziness	B-Disease
was	O
less	O
marked	O
than	O
sedation	O
,	O
but	O
increased	O
with	O
the	O
dose	O
.	O

The	O
effect	O
of	O
long	O
-	O
term	O
timolol	B-Chemical
treatment	O
on	O
heart	O
size	O
after	O
myocardial	B-Disease
infarction	I-Disease
was	O
evaluated	O
by	O
X	O
-	O
ray	O
in	O
a	O
double	O
-	O
blind	O
study	O
including	O
241	O
patients	O
(	O
placebo	O
126	O
,	O
timolol	B-Chemical
115	O
).	O
The	O
follow	O
-	O
up	O
period	O
was	O
12	O
months	O
.	O

The	O
timolol	B-Chemical
-	O
treated	O
patients	O
showed	O
a	O
small	O
but	O
significant	O
increase	O
in	O
heart	O
size	O
from	O
baseline	O
in	O
contrast	O
to	O
a	O
decrease	O
in	O
the	O
placebo	O
group	O
.	O

In	O
patients	O
with	O
cardiomegaly	B-Disease
,	O
the	O
increase	O
in	O
heart	O
size	O
was	O
similar	O
in	O
both	O
groups	O
.	O

After	O
re	O
-	O
infarction	B-Disease
,	O
heart	O
size	O
increased	O
in	O
the	O
placebo	O
group	O
and	O
remained	O
unchanged	O
in	O
the	O
timolol	B-Chemical

Large	O
parenteral	O
doses	O
of	O
vitamin	B-Chemical
D3	I-Chemical
(	O
15	O
to	O
17	O
.	O

5	O
x	O
10	O
(	O
6	O
)	O
IU	O
vitamin	B-Chemical
D3	I-Chemical
)	O
were	O
associated	O
with	O
prolonged	O
hypercalcemia	B-Disease
,	O
hyperphosphatemia	B-Disease
,	O
and	O
large	O
increases	O
of	O
vitamin	B-Chemical
D3	I-Chemical
and	O
its	O
metabolites	O
in	O
the	O
blood	O
plasma	O
of	O
nonlactating	O
nonpregnant	O
and	O
pregnant	O
Jersey	O
cows	O
.	O

Signs	O
of	O
vitamin	B-Chemical
D3	I-Chemical
toxicity	B-Disease
were	O
not	O
observed	O
in	O
nonlactating	O
nonpregnant	O
cows	O
;	O
however	O
,	O
pregnant	O
cows	O
commonly	O
developed	O
severe	O
signs	O
of	O
vitamin	B-Chemical
D3	I-Chemical
toxicity	B-Disease
and	O
10	O
of	O
17	O
cows	O
died	O
.	O

The	O
anatomical	O
and	O
aetiological	O
diagnoses	O
of	O
peripheral	B-Disease
nerve	I-Disease
disease	I-Disease
excluding	O
its	O
primary	O
benign	O
and	O
malignant	O
disorders	O
,	O
as	O
seen	O
in	O
358	O
Nigerians	O
are	O
presented	O
.	O

6	O
%),	O
accounting	O
for	O
half	O
of	O
the	O
cases	O
with	O
motor	B-Disease
neuropathy	I-Disease
.	O

Peripheral	B-Disease
neuropathy	I-Disease
due	O
to	O
nutritional	B-Disease
deficiency	I-Disease
of	O
thiamine	B-Chemical
and	O
riboflavin	B-Chemical
was	O
common	O
(	O
10	O
.	O

Diabetes	B-Disease
mellitus	I-Disease
was	O
the	O
major	O
cause	O
of	O
autonomic	B-Disease
neuropathy	I-Disease
.	O

5	O
%	O
of	O
all	O
the	O
cases	O
,	O
the	O
aetiology	O
of	O
the	O
neuropathy	B-Disease
was	O
undetermined	O
.	O

Some	O
of	O
the	O
factors	O
related	O
to	O
the	O
clinical	O
presentation	O
and	O
pathogenesis	O
of	O
the	O
neuropathies	B-Disease

A	O
double	O
-	O
blind	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
dothiepin	B-Chemical
hydrochloride	I-Chemical
in	O
the	O
treatment	O
of	O
major	O
depressive	B-Disease
disorder	I-Disease
.	O

Dothiepin	B-Chemical
and	O
amitriptyline	B-Chemical
were	O
equally	O
effective	O
in	O
alleviating	O
the	O
symptoms	O
of	O
depressive	B-Disease
illness	I-Disease
,	O
and	O
both	O
were	O
significantly	O
superior	O
to	O
placebo	O
.	O

Dothiepin	B-Chemical
also	O
produced	O
fewer	O
CNS	O
and	O
cardiovascular	O
effects	O
.	O

Dothiepin	B-Chemical
thus	O
was	O
found	O
to	O
be	O
an	O
effective	O
antidepressant	B-Chemical
drug	O
associated	O
with	O
fewer	O
side	O
effects	O
than	O
amitriptyline	B-Chemical
in	O
the	O
treatment	O
of	O
depressed	B-Disease

The	O
effects	O
of	O
oral	O
doses	O
of	O
diazepam	B-Chemical
(	O
single	O
dose	O
of	O
10	O
mg	O
and	O
a	O
median	O
dose	O
of	O
30	O
mg	O
/	O
day	O
for	O
2	O
weeks	O
)	O
and	O
propranolol	B-Chemical
(	O
single	O
dose	O
of	O
80	O
mg	O
and	O
a	O
median	O
dose	O
of	O
240	O
mg	O
/	O
day	O
for	O
2	O
weeks	O
)	O
on	O
psychological	O
performance	O
of	O
patients	O
with	O
panic	B-Disease
disorders	I-Disease
and	O
agoraphobia	B-Disease
were	O
investigated	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
and	O
crossover	O
design	O
.	O

Accumulation	O
of	O
drugs	O
was	O
not	O
reflected	O
in	O
prolonged	O
behavioral	B-Disease
impairment	I-Disease

Effect	O
of	O
aspirin	B-Chemical
on	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	B-Chemical
-	O
induced	O
epithelial	O
proliferation	O
in	O
the	O
urinary	O
bladder	O
and	O
forestomach	O
of	O
the	O
rat	O
.	O

The	O
co	O
-	O
administration	O
of	O
aspirin	B-Chemical
with	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	B-Chemical
(	O
FANFT	B-Chemical
)	O
to	O
rats	O
resulted	O
in	O
a	O
reduced	O
incidence	O
of	O
FANFT	B-Chemical
-	O
induced	O
bladder	B-Disease
carcinomas	I-Disease
but	O
a	O
concomitant	O
induction	O
of	O
forestomach	B-Disease
tumors	I-Disease
.	O

2	O
%	O
and	O
/	O
or	O
aspirin	B-Chemical
at	O
a	O
level	O
of	O
0	O
.	O

FANFT	B-Chemical
-	O
induced	O
cell	O
proliferation	O
in	O
the	O
bladder	O
was	O
significantly	O
suppressed	O
by	O
aspirin	B-Chemical
co	O
-	O
administration	O
after	O
4	O
weeks	O
but	O
not	O
after	O
12	O
weeks	O
.	O

Also	O
,	O
there	O
appears	O
to	O
be	O
an	O
adaptation	O
by	O
the	O
rats	O
to	O
the	O
chronic	O
ingestion	O
of	O
aspirin	B-Chemical

Provocation	O
of	O
postural	O
hypotension	B-Disease
by	O
nitroglycerin	B-Chemical
in	O
diabetic	B-Disease
autonomic	I-Disease
neuropathy	I-Disease
?	O
The	O
effect	O
of	O
nitroglycerin	B-Chemical
on	O
heart	O
rate	O
and	O
systolic	O
blood	O
pressure	O
was	O
compared	O
in	O
5	O
normal	O
subjects	O
,	O
12	O
diabetic	B-Disease
subjects	O
without	O
autonomic	B-Disease
neuropathy	I-Disease
,	O
and	O
5	O
diabetic	B-Disease
subjects	O
with	O
autonomic	B-Disease
neuropathy	I-Disease
.	O

Characterization	O
of	O
estrogen	B-Chemical
-	O
induced	O
adenohypophyseal	B-Disease
tumors	I-Disease
in	O
the	O
Fischer	O
344	O
rat	O
.	O

The	O
cell	O
populations	O
were	O
examined	O
regarding	O
total	O
cell	O
recovery	O
correlated	O
with	O
gland	O
weight	O
,	O
intracellular	O
prolactin	O
(	O
PRL	O
)	O
content	O
and	O
subsequent	O
release	O
in	O
primary	O
culture	O
,	O
immunocytochemical	O
PRL	O
staining	O
,	O
density	O
and	O
/	O
or	O
size	O
alterations	O
via	O
separation	O
on	O
Ficoll	O
-	O
Hypaque	O
and	O
by	O
unit	O
gravity	O
sedimentation	O
,	O
and	O
cell	O
cycle	O
analysis	O
,	O
after	O
acriflavine	B-Chemical
DNA	O
staining	O
,	O
by	O
laser	O
flow	O
cytometry	O
.	O

4	O
times	O
control	O
levels	O
,	O
and	O
PRL	O
release	O
in	O
vitro	O
was	O
significantly	O
and	O
consistently	O
higher	O
than	O
controls	O
,	O
after	O
at	O
least	O
8	O
days	O
of	O
DES	B-Chemical
exposure	O
.	O

All	O
these	O
effects	O
of	O
DES	B-Chemical
were	O
more	O
pronounced	O
among	O
previously	O
ovariectomized	O
animals	O
.	O

The	O
data	O
extend	O
the	O
findings	O
of	O
other	O
investigators	O
,	O
further	O
establishing	O
the	O
DES	B-Chemical
-	O
induced	O
tumor	B-Disease

A	O
case	O
of	O
triamterene	B-Chemical
nephrolithiasis	B-Disease
is	O
reported	O
in	O
a	O
man	O
after	O
4	O
years	O
of	O
hydrochlorothiazide-triamterene	B-Chemical
therapy	O
for	O
hypertension	B-Disease
.	O

Metabolic	O
involvement	O
in	O
adriamycin	B-Chemical
cardiotoxicity	B-Disease
.	O

Adriamycin	B-Chemical
inhibited	O
cell	O
growth	O
and	O
the	O
rhythmic	O
contractions	O
characteristic	O
of	O
myocardial	O
cells	O
in	O
culture	O
.	O

The	O
adenylate	O
energy	O
charge	O
was	O
found	O
to	O
be	O
significantly	O
decreased	O
,	O
while	O
the	O
phophorylcreatine	B-Chemical
mole	O
fraction	O
was	O
unchanged	O
.	O

The	O
addition	O
of	O
1	O
mM	O
adenosine	B-Chemical
to	O
the	O
myocardial	O
cell	O
cultures	O
markedly	O
increases	O
the	O
ATP	B-Chemical
concentration	O
through	O
a	O
pathway	O
reportedly	O
leading	O
to	O
a	O
compartmentalized	O
ATP	B-Chemical
pool	O
.	O

Age	O
-	O
dependent	O
sensitivity	O
of	O
the	O
rat	O
to	O
neurotoxic	B-Disease
effects	O
of	O
streptomycin	B-Chemical
.	O

Streptomycin	B-Chemical
sulfate	O
(	O
300	O
mg	O
/	O
kg	O
s	O
.	O

Crescentic	O
fibrillary	O
glomerulonephritis	B-Disease
associated	O
with	O
intermittent	O
rifampin	B-Chemical
therapy	O
for	O
pulmonary	B-Disease
tuberculosis	I-Disease
.	O

This	O
patient	O
underwent	O
a	O
10	O
-	O
month	O
regimen	O
of	O
rifampin	B-Chemical
and	O
isoniazid	B-Chemical
for	O
pulmonary	B-Disease
tuberculosis	I-Disease
and	O
was	O
discovered	O
to	O
have	O
developed	O
signs	O
of	O
severe	O
renal	B-Disease
failure	I-Disease
five	O
weeks	O
after	O
completion	O
of	O
therapy	O
.	O

Renal	O
biopsy	O
revealed	O
severe	O
glomerulonephritis	B-Disease
with	O
crescents	O
,	O
electron	O
dense	O
fibrillar	O
deposits	O
and	O
moderate	O
lymphocytic	O
interstitial	O
infiltrate	O
.	O

Time	O
course	O
of	O
lipid	O
peroxidation	O
in	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephropathy	B-Disease
.	O

The	O
temporal	O
relationship	O
between	O
lipid	O
peroxidation	O
in	O
the	O
kidney	O
and	O
proteinuria	B-Disease
was	O
examined	O
in	O
this	O
study	O
.	O

Tissue	O
lipid	O
peroxidation	O
was	O
measured	O
in	O
whole	O
homogenates	O
as	O
well	O
as	O
in	O
lipid	O
extracts	O
from	O
homogenates	O
as	O
thiobarbituric	B-Chemical
acid	I-Chemical
reactive	O
substances	O
.	O

This	O
study	O
supports	O
the	O
role	O
of	O
lipid	O
peroxidation	O
in	O
mediating	O
the	O
proteinuric	B-Disease
injury	I-Disease
in	O
PAN	B-Chemical
nephropathy	B-Disease

The	O
present	O
study	O
was	O
undertaken	O
to	O
examine	O
the	O
role	O
of	O
sleep	B-Disease
disturbance	I-Disease
,	O
induced	O
by	O
clomipramine	B-Chemical
administration	O
,	O
on	O
the	O
secretory	O
rate	O
of	O
prolactin	O
(	O
PRL	O
)	O
in	O
addition	O
to	O
the	O
direct	O
drug	O
effect	O
.	O

During	O
the	O
night	O
clomipramine	B-Chemical
ingestion	O
altered	O
the	O
complete	O
sleep	O
architecture	O
in	O
that	O
it	O
suppressed	O
REM	O
sleep	O
and	O
the	O
sleep	O
cycles	O
and	O
induced	O
increased	O
wakefulness	O
.	O

As	O
the	O
relative	O
increase	O
in	O
PRL	O
secretion	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
mean	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
night	O
and	O
day	O
time	O
studies	O
(	O
46	O
+/-	O
19	O
%	O
vs	O
34	O
+/-	O
10	O
%),	O
it	O
can	O
be	O
concluded	O
that	O
the	O
observed	O
sleep	B-Disease
disturbance	I-Disease
did	O
not	O
interfere	O
with	O
the	O
drug	O
action	O
per	O
se	O
.	O

Her	O
medical	O
history	O
included	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
with	O
previous	O
myocardial	B-Disease
infarctions	I-Disease
,	O
hypertension	B-Disease
,	O
and	O
diabetes	B-Disease
mellitus	I-Disease
.	O

A	O
history	O
of	O
angioedema	B-Disease
secondary	O
to	O
lisinopril	B-Chemical
therapy	O
was	O
elicited	O
.	O

Current	O
medications	O
did	O
not	O
include	O
angiotensin	B-Chemical
-	O
converting	O
enzyme	O
inhibitors	O
or	O
beta	O
-	O
blockers	O
.	O

The	O
angioedema	B-Disease
resolved	O
after	O
therapy	O
with	O
intravenous	O
steroids	B-Chemical
and	O
diphenhydramine	B-Chemical

Coniine	B-Chemical
,	O
an	O
alkaloid	O
from	O
Conium	O
maculatum	O
(	O
poison	O
hemlock	O
),	O
has	O
been	O
shown	O
to	O
be	O
teratogenic	O
in	O
livestock	O
.	O

Concentrations	O
of	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
sulfate	O
were	O
0	O
.	O

Both	O
compounds	O
caused	O
deformations	B-Disease
and	O
lethality	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

75	O
%.	O
The	O
deformations	B-Disease
caused	O
by	O
both	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
sulfate	O
were	O
excessive	B-Disease
flexion	I-Disease
or	I-Disease
extension	I-Disease
of	I-Disease
one	I-Disease
or	I-Disease
more	I-Disease
toes	I-Disease
.	O

01	O
)	O
decrease	O
in	O
movement	O
in	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
sulfate	O
treated	O
chicks	O
as	O
determined	O
by	O
ultrasound	O
.	O

95	O
%	O
of	O
a	O
5	O
-	O
min	O
interval	O
,	O
and	O
no	O
movement	O
was	O
observed	O
for	O
nicotine	B-Chemical
sulfate	O
treated	O
chicks	O
.	O

In	O
summary	O
,	O
the	O
chick	O
embryo	O
provides	O
a	O
reliable	O
and	O
simple	O
experimental	O
animal	O
model	O
of	O
coniine	B-Chemical
-	O
induced	O
arthrogryposis	B-Disease

To	O
evaluate	O
the	O
effect	O
of	O
prostaglandin	B-Chemical
E1	I-Chemical
(	O
PGE1	B-Chemical
)	O
or	O
trimethaphan	B-Chemical
(	O
TMP	B-Chemical
)	O
induced	O
hypotension	B-Disease
on	O
epidural	O
blood	O
flow	O
(	O
EBF	O
)	O
during	O
spinal	O
surgery	O
,	O
EBF	O
was	O
measured	O
using	O
the	O
heat	O
clearance	O
method	O
in	O
30	O
patients	O
who	O
underwent	O
postero	O
-	O
lateral	O
interbody	O
fusion	O
under	O
isoflurane	B-Chemical
anaesthesia	O
.	O

min	O
-	O
1	O
of	O
TMP	B-Chemical
(	O
15	O
patients	O
)	O
was	O
administered	O
intravenously	O
after	O
the	O
dural	O
opening	O
and	O
the	O
dose	O
was	O
adjusted	O
to	O
maintain	O
the	O
mean	O
arterial	O
blood	O
pressure	O
(	O
MAP	O
)	O
at	O
about	O
60	O
mmHg	O
.	O

EBFF	O
did	O
not	O
change	O
during	O
PGE1	B-Chemical
infusion	O
whereas	O
in	O
the	O
TMP	B-Chemical
group	O
,	O
EBF	O
decreased	O
significantly	O
at	O
30	O
and	O
60	O
min	O
after	O
the	O
start	O
of	O
TMP	B-Chemical
(	O
preinfusion	O
:	O
45	O
.	O

05	O
)).	O
These	O
results	O
suggest	O
that	O
PGE1	B-Chemical
may	O
be	O
preferable	O
to	O
TMP	B-Chemical
for	O
hypotensive	B-Disease
anaesthesia	O
in	O
spinal	O
surgery	O
because	O
TMP	B-Chemical

Immunohistochemical	O
studies	O
with	O
antibodies	O
to	O
neurofilament	O
proteins	O
on	O
axonal	B-Disease
damage	I-Disease
in	O
experimental	O
focal	O
lesions	O
in	O
rat	O
.	O

Infarcts	B-Disease
in	I-Disease
substantia	I-Disease
nigra	I-Disease
pars	I-Disease
reticulata	I-Disease
were	O
evoked	O
by	O
prolonged	O
pilocarpine	B-Chemical
-	O
induced	O
status	B-Disease
epilepticus	I-Disease
.	O

These	O
immunohistochemical	O
changes	O
of	O
NFs	O
can	O
serve	O
as	O
a	O
marker	O
for	O
axonal	B-Disease
damage	I-Disease
in	O
various	O
experimental	O
traumatic	B-Disease

We	O
report	O
the	O
increased	O
amount	O
of	O
motor	B-Disease
disability	I-Disease
in	O
four	O
patients	O
with	O
idiopathic	B-Disease
Parkinson's	I-Disease
disease	I-Disease
after	O
exposure	O
to	O
the	O
antidepressant	B-Chemical
fluoxetine	B-Chemical
.	O

Acetaminophen	B-Chemical
-	O
induced	O
hypotension	B-Disease
.	O

However	O
,	O
acetaminophen	B-Chemical
has	O
been	O
demonstrated	O
to	O
produce	O
symptoms	O
of	O
anaphylaxis	B-Disease
,	O
including	O
hypotension	B-Disease
,	O
in	O
sensitive	O
individuals	O
.	O

Other	O
symptoms	O
of	O
allergic	B-Disease
reactions	I-Disease
were	O
not	O
clinically	O
detectable	O
.	O

The	O
reports	O
illustrate	O
the	O
need	O
for	O
clinicians	O
to	O
consider	O
acetaminophen	B-Chemical
in	O
patients	O
with	O
hypotension	B-Disease

An	O
80	O
-	O
yr	O
-	O
old	O
man	O
developed	O
acute	O
hepatitis	B-Disease
shortly	O
after	O
ingesting	O
oral	O
ceftriaxone	B-Chemical
.	O

These	O
responded	O
to	O
systemic	O
steroids	B-Chemical
and	O
immunoglobulins	O
.	O

Conventional	O
agents	O
are	O
associated	O
with	O
unwanted	O
central	O
nervous	O
system	O
effects	O
,	O
including	O
extrapyramidal	B-Disease
symptoms	I-Disease
(	O
EPS	B-Disease
),	O
tardive	B-Disease
dyskinesia	I-Disease
,	O
sedation	O
,	O
and	O
possible	O
impairment	O
of	O
some	O
cognitive	O
measures	O
,	O
as	O
well	O
as	O
cardiac	O
effects	O
,	O
orthostatic	B-Disease
hypotension	I-Disease
,	O
hepatic	O
changes	O
,	O
anticholinergic	O
side	O
effects	O
,	O
sexual	B-Disease
dysfunction	I-Disease
,	O
and	O
weight	B-Disease
gain	I-Disease
.	O

The	O
newer	O
atypical	O
agents	O
have	O
a	O
lower	O
risk	O
of	O
EPS	B-Disease
,	O
but	O
are	O
associated	O
in	O
varying	O
degrees	O
with	O
sedation	O
,	O
cardiovascular	O
effects	O
,	O
anticholinergic	O
effects	O
,	O
weight	B-Disease
gain	I-Disease
,	O
sexual	B-Disease
dysfunction	I-Disease
,	O
hepatic	O
effects	O
,	O
lowered	O
seizure	B-Disease
threshold	O
(	O
primarily	O
clozapine	B-Chemical
),	O
and	O
agranulocytosis	B-Disease
(	O
clozapine	B-Chemical

Tetrandrine	B-Chemical
(	O
TET	B-Chemical
)	O
and	O
fangchinoline	B-Chemical
(	O
FAN	B-Chemical
)	O
are	O
two	O
naturally	O
occurring	O
analogues	O
with	O
a	O
bisbenzylisoquinoline	B-Chemical
structure	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
on	O
the	O
experimental	O
thrombosis	B-Disease
induced	O
by	O
collagen	O
plus	O
epinephrine	B-Chemical
(	O
EP	B-Chemical
)	O
in	O
mice	O
,	O
and	O
platelet	B-Disease
aggregation	I-Disease
and	O
blood	B-Disease
coagulation	I-Disease
in	O
vitro	O
.	O

In	O
the	O
vitro	O
human	O
platelet	B-Disease
aggregations	I-Disease
induced	O
by	O
the	O
agonists	O
used	O
in	O
tests	O
,	O
TET	B-Chemical
and	O
FAN	B-Chemical
showed	O
the	O
inhibitions	O
dose	O
dependently	O
.	O

These	O
results	O
suggest	O
that	O
antithrombosis	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical

Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	O
with	O
vinorelbine	B-Chemical
(	O
VNB	B-Chemical
)	O
or	O
gemcitabine	B-Chemical
(	O
GEM	B-Chemical
)	O
may	O
obtain	O
a	O
response	O
rate	O
of	O
20	O
-	O
30	O
%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	B-Disease
and	O
improvement	O
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O

METHODS	O
:	O
Forty	O
-	O
nine	O
patients	O
with	O
advanced	O
NSCLC	B-Disease
were	O
included	O
,	O
38	O
of	O
whom	O
were	O
age	O
>/=	O
70	O
years	O
and	O
11	O
were	O
age	O
<	O
70	O
years	O
but	O
who	O
had	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	B-Chemical
.	O

All	O
patients	O
were	O
evaluable	O
for	O
response	O
and	O
toxicity	B-Disease
.	O

Six	O
patients	O
(	O
12	O
%)	O
had	O
World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	B-Disease
,	O
2	O
patients	O
(	O
4	O
%)	O
had	O
Grade	O
3	O
-	O
4	O
thrombocytopenia	B-Disease
,	O
and	O
2	O
patients	O
(	O
4	O
%)	O
had	O
Grade	O
3	O
neurotoxicity	B-Disease
.	O

The	O
median	O
age	O
of	O
those	O
patients	O
developing	O
Grade	O
3	O
-	O
4	O
neutropenia	B-Disease
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
remaining	O
patients	O
(	O
75	O
years	O
vs	O
.	O

047	O
).	O
CONCLUSIONS	O
:	O
The	O
combination	O
of	O
GEM	B-Chemical
and	O
VNB	B-Chemical
is	O
moderately	O
active	O
and	O
well	O
tolerated	O
except	O
in	O
patients	O
age	O
>/=	O
75	O
years	O
.	O

New	O
chemotherapy	O
combinations	O
with	O
higher	O
activity	O
and	O
lower	O
toxicity	B-Disease
are	O
needed	O
for	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	B-Disease

The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	B-Chemical
D	I-Chemical
treatment	O
enhance	O
the	O
extent	O
of	O
artery	B-Disease
calcification	I-Disease
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	B-Chemical
to	O
inhibit	O
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	B-Disease
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

Treatment	O
for	O
2	O
weeks	O
with	O
Warfarin	B-Chemical
caused	O
massive	O
focal	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
20	O
-	O
day	O
-	O
old	O
rats	O
and	O
less	O
extensive	O
focal	O
calcification	B-Disease
in	O
42	O
-	O
day	O
-	O
old	O
rats	O
.	O

To	O
directly	O
examine	O
the	O
importance	O
of	O
growth	O
to	O
Warfarin	B-Chemical
-	O
induced	O
artery	B-Disease
calcification	I-Disease
in	O
animals	O
of	O
the	O
same	O
age	O
,	O
20	O
-	O
day	O
-	O
old	O
rats	O
were	O
fed	O
for	O
2	O
weeks	O
either	O
an	O
ad	O
libitum	O
diet	O
or	O
a	O
6	O
-	O
g	O
/	O
d	O
restricted	O
diet	O
that	O
maintains	O
weight	O
but	O
prevents	O
growth	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	B-Disease
calcification	I-Disease
and	O
growth	O
status	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	B-Chemical
and	O
susceptibility	O
to	O
artery	B-Disease
calcification	I-Disease
,	O
with	O
30	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	B-Chemical
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	O
to	O
Warfarin	B-Chemical
-	O
induced	O
artery	B-Disease
calcification	I-Disease
,	O
ie	O
,	O
the	O
10	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O

The	O
second	O
set	O
of	O
experiments	O
examined	O
the	O
possible	O
synergy	O
between	O
vitamin	B-Chemical
D	I-Chemical
and	O
Warfarin	B-Chemical
in	O
artery	B-Disease
calcification	I-Disease
.	O

High	O
doses	O
of	O
the	O
vitamin	B-Chemical
K	I-Chemical
antagonist	O
Warfarin	B-Chemical
are	O
also	O
known	O
to	O
cause	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
,	O
but	O
at	O
treatment	O
times	O
of	O
2	O
weeks	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	B-Chemical
D	I-Chemical
dose	O
on	O
artery	B-Disease
calcification	I-Disease
and	O
the	O
effect	O
of	O
vitamin	B-Chemical
D	I-Chemical
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	B-Chemical
,	O
which	O
suggests	O
that	O
vitamin	B-Chemical
D	I-Chemical
may	O
induce	O
artery	B-Disease
calcification	I-Disease
through	O
its	O
effect	O
on	O
serum	O
calcium	B-Chemical
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	B-Disease
calcification	I-Disease
in	O
rats	O
treated	O
with	O
vitamin	B-Chemical
D	I-Chemical
plus	O
Warfarin	B-Chemical
,	O
and	O
chemical	O
analysis	O
showed	O
that	O
the	O
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma-carboxylated	B-Chemical
.	O

Antidepressant	B-Chemical
-	O
induced	O
mania	B-Disease
in	O
bipolar	B-Disease
patients	O
:	O
identification	O
of	O
risk	O
factors	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	B-Disease
or	O
hypomanic	B-Disease
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM-IV	B-Disease
bipolar	I-Disease
I	I-Disease
vs	O
.	O

bipolar	B-Disease
II	I-Disease
),	O
number	O
of	O
previous	O
manic	B-Disease
episodes	O
,	O
type	O
of	O
antidepressant	B-Chemical
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O

bipolar	B-Disease
II	I-Disease
),	O
and	O
additional	O
treatment	O
did	O
not	O
affect	O
the	O
risk	O
of	O
switching	O
.	O

In	O
contrast	O
,	O
mood	O
switches	O
were	O
less	O
frequent	O
in	O
patients	O
receiving	O
lithium	B-Chemical
(	O
15	O
%,	O
4	O
/	O
26	O
)	O
than	O
in	O
patients	O
not	O
treated	O
with	O
lithium	B-Chemical
(	O
44	O
%,	O
8	O
/	O
18	O
;	O
p	O
=.	O
04	O
).	O
The	O
number	O
of	O
previous	O
manic	B-Disease
episodes	O
did	O
not	O
affect	O
the	O
probability	O
of	O
switching	O
,	O
whereas	O
a	O
high	O
score	O
on	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semistructured	O
Affective	O
Temperament	O
Interview	O
was	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
switching	O
(	O
p	O
=.	O
008	O
).	O
CONCLUSION	O
:	O
The	O
frequency	O
of	O
mood	O
switching	O
associated	O
with	O
acute	O
antidepressant	B-Chemical
therapy	O
may	O
be	O
reduced	O
by	O
lithium	B-Chemical

We	O
describe	O
a	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
pre	O
-	O
existing	O
mitral	B-Disease
valve	I-Disease
prolapse	I-Disease
who	O
developed	O
intractable	O
ventricular	B-Disease
fibrillation	I-Disease
after	O
consuming	O
a	O
"	O
natural	O
energy	O
"	O
guarana	O
health	O
drink	O
containing	O
a	O
high	O
concentration	O
of	O
caffeine	B-Chemical

Fentanyl	B-Chemical
,	O
an	O
opioid	O
analgesic	O
,	O
is	O
frequently	O
used	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
setting	O
for	O
these	O
very	O
purposes	O
.	O

Various	O
reported	O
side	O
effects	O
of	O
fentanyl	B-Chemical
administration	O
include	O
chest	B-Disease
wall	I-Disease
rigidity	I-Disease
,	O
hypotension	B-Disease
,	O
respiratory	B-Disease
depression	I-Disease
,	O
and	O
bradycardia	B-Disease
.	O

Combined	O
antiretroviral	O
therapy	O
causes	O
cardiomyopathy	B-Disease
and	O
elevates	O
plasma	O
lactate	B-Chemical
in	O
transgenic	O
AIDS	B-Disease
mice	O
.	O

To	O
determine	O
mitochondrial	O
events	O
from	O
HAART	O
in	O
vivo	O
,	O
8	O
-	O
week	O
-	O
old	O
hemizygous	O
transgenic	O
AIDS	B-Disease
mice	O
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	O
;	O
TG	O
)	O
and	O
wild	O
-	O
type	O
FVB	O
/	O
n	O
littermates	O
were	O
treated	O
with	O
the	O
HAART	O
combination	O
of	O
zidovudine	B-Chemical
,	O
lamivudine	B-Chemical
,	O
and	O
indinavir	B-Chemical
or	O
vehicle	O
control	O
for	O
10	O
days	O
or	O
35	O
days	O
.	O

Results	O
show	O
that	O
cumulative	O
HAART	O
caused	O
mitochondrial	O
CM	B-Disease
with	O
elevated	O
LA	B-Chemical
in	O
AIDS	B-Disease

BACKGROUND	O
:	O
An	O
association	O
between	O
the	O
use	O
of	O
oral	B-Chemical
contraceptives	I-Chemical
and	O
the	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
has	O
been	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
studies	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	B-Chemical
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O

Subjects	O
supplied	O
information	O
on	O
oral-contraceptive	B-Chemical
use	O
and	O
major	O
cardiovascular	O
risk	O
factors	O
.	O

An	O
analysis	O
for	O
factor	O
V	O
Leiden	O
and	O
the	O
G20210A	O
mutation	O
in	O
the	O
prothrombin	O
gene	O
was	O
conducted	O
in	O
217	O
patients	O
and	O
763	O
controls	O
RESULTS	O
:	O
The	O
odds	O
ratio	O
for	O
myocardial	B-Disease
infarction	I-Disease
among	O
women	O
who	O
used	O
any	O
type	O
of	O
combined	O
oral	B-Chemical
contraceptive	I-Chemical
,	O
as	O
compared	O
with	O
nonusers	O
,	O
was	O
2	O
.	O

5	O
)	O
among	O
those	O
who	O
used	O
third	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

The	O
results	O
with	O
respect	O
to	O
the	O
use	O
of	O
third	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
were	O
inconclusive	O
but	O
suggested	O
that	O
the	O
risk	O
was	O
lower	O
than	O
the	O
risk	O
associated	O
with	O
second	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

The	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
was	O
similar	O
among	O
women	O
who	O
used	O
oral	B-Chemical
contraceptives	I-Chemical

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
effect	O
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
subregions	O
of	O
the	O
nucleus	O
accumbens	O
(	O
the	O
shell	O
and	O
the	O
core	O
)	O
on	O
the	O
locomotor	B-Disease
hyperactivity	I-Disease
induced	O
by	O
cocaine	B-Chemical
in	O
rats	O
.	O

1	O
-	O
10	O
microg	O
/	O
side	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
0	O
.	O

GR	B-Chemical
55562	I-Chemical
(	O
0	O
.	O

When	O
injected	O
into	O
the	O
accumbens	O
shell	O
(	O
but	O
not	O
the	O
core	O
)	O
before	O
cocaine	B-Chemical
,	O
CP	B-Chemical
93129	I-Chemical
(	O
0	O
.	O

The	O
later	O
enhancement	O
was	O
attenuated	O
after	O
intra	O
-	O
accumbens	O
shell	O
treatment	O
with	O
GR	B-Chemical
55562	I-Chemical
(	O
1	O
microg	O
/	O
side	O
).	O
Our	O
findings	O
indicate	O
that	O
cocaine	B-Chemical
induced	O
hyperlocomotion	B-Disease
is	O
modified	O
by	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbens	O
shell	O
,	O
but	O
not	O
core	O
,	O
this	O
modification	O
consisting	O
in	O
inhibitory	O
and	O
facilitatory	O
effects	O
of	O
the	O
5	O
-	O
HT1B	O
receptor	O
antagonist	O
(	O
GR	B-Chemical
55562	I-Chemical
)	O
and	O
agonist	O
(	O
CP	B-Chemical
93129	I-Chemical

OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	O
of	O
ticlopidine	B-Chemical
-	O
induced	O
cholestatic	B-Disease
hepatitis	I-Disease
,	O
investigate	O
its	O
mechanism	O
,	O
and	O
compare	O
the	O
observed	O
main	O
characteristics	O
with	O
those	O
of	O
the	O
published	O
cases	O
.	O

T	O
-	O
cell	O
stimulation	O
by	O
therapeutic	O
concentration	O
of	O
ticlopidine	B-Chemical
was	O
demonstrated	O
in	O
vitro	O
in	O
the	O
patients	O
,	O
but	O
not	O
in	O
healthy	O
controls	O
.	O

DISCUSSION	O
:	O
Cholestatic	B-Disease
hepatitis	I-Disease
is	O
a	O
rare	O
complication	O
of	O
the	O
antiplatelet	O
agent	O
ticlopidine	B-Chemical
;	O
several	O
cases	O
have	O
been	O
reported	O
but	O
few	O
in	O
the	O
English	O
literature	O
.	O

Hepatitis	B-Disease
may	O
develop	O
weeks	O
after	O
discontinuation	O
of	O
the	O
drug	O
and	O
may	O
run	O
a	O
prolonged	O
course	O
,	O
but	O
complete	O
remission	O
was	O
observed	O
in	O
all	O
reported	O
cases	O
.	O

The	O
mechanisms	O
of	O
this	O
ticlopidine	B-Chemical
-	O
induced	O
cholestasis	B-Disease
are	O
unclear	O
.	O

This	O
complication	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
ticlopidine	B-Chemical
is	O
being	O
replaced	O
by	O
the	O
newer	O
antiplatelet	O
agent	O
clopidogrel	B-Chemical

Epithelial	O
sodium	B-Chemical
channel	O
(	O
ENaC	O
)	O
subunit	O
mRNA	O
and	O
protein	O
expression	O
in	O
rats	O
with	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O

The	O
rate	O
-	O
limiting	O
constituent	O
of	O
collecting	O
duct	O
sodium	B-Chemical
transport	O
is	O
the	O
epithelial	O
sodium	B-Chemical
channel	O
(	O
ENaC	O
).	O
We	O
examined	O
the	O
abundance	O
of	O
ENaC	O
subunit	O
mRNAs	O
and	O
proteins	O
in	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
)-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O

The	O
kinetics	O
of	O
urinary	O
sodium	B-Chemical
excretion	O
and	O
the	O
appearance	O
of	O
proteinuria	B-Disease
were	O
comparable	O
with	O
those	O
reported	O
previously	O
.	O

A	O
significant	O
up	O
-	O
regulation	O
of	O
alphaENaC	O
and	O
betaENaC	O
mRNA	O
abundance	O
on	O
days	O
1	O
and	O
2	O
preceded	O
sodium	B-Chemical
retention	O
on	O
days	O
2	O
and	O
3	O
.	O

The	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
proteins	O
were	O
not	O
increased	O
during	O
PAN	B-Chemical
-	O
induced	O
sodium	B-Chemical
retention	O
.	O

NO	B-Chemical
-	O
induced	O
migraine	B-Disease
attack	O
:	O
strong	O
increase	O
in	O
plasma	O
calcitonin	B-Chemical
gene-related	I-Chemical
peptide	I-Chemical
(	O
CGRP	B-Chemical
)	O
concentration	O
and	O
negative	O
correlation	O
with	O
platelet	O
serotonin	B-Chemical
release	O
.	O

Fifteen	O
female	O
migraineurs	B-Disease
(without	I-Disease
aura)	I-Disease
and	O
eight	O
controls	O
participated	O
in	O
the	O
study	O
.	O

Blood	O
was	O
collected	O
from	O
the	O
antecubital	O
vein	O
four	O
times	O
:	O
60	O
min	O
before	O
and	O
after	O
the	O
nitroglycerin	B-Chemical
application	O
,	O
and	O
60	O
and	O
120	O
min	O
after	O
the	O
beginning	O
of	O
the	O
migraine	B-Disease
attack	O
(	O
mean	O
344	O
and	O
404	O
min	O
;	O
12	O
subjects	O
).	O
In	O
those	O
subjects	O
who	O
had	O
no	O
migraine	B-Disease
attack	O
(	O
11	O
subjects	O
)	O
a	O
similar	O
time	O
schedule	O
was	O
used	O
.	O

Plasma	O
CGRP	B-Chemical
concentration	O
increased	O
significantly	O
(	O
P	O
<	O
0	O
.	O

In	O
addition	O
,	O
both	O
change	O
and	O
peak	O
,	O
showed	O
significant	O
positive	O
correlations	O
with	O
migraine	B-Disease
headache	B-Disease
intensity	O
(	O
P	O
<	O
0	O
.	O

Basal	O
CGRP	B-Chemical
concentration	O
was	O
significantly	O
higher	O
and	O
platelet	O
5-HT	B-Chemical
content	O
tended	O
to	O
be	O
lower	O
in	O
subjects	O
who	O
experienced	O
a	O
migraine	B-Disease
attack	O
.	O

In	O
conclusion	O
,	O
the	O
fact	O
that	O
plasma	O
CGRP	B-Chemical
concentration	O
correlates	O
with	O
the	O
timing	O
and	O
severity	O
of	O
a	O
migraine	B-Disease
headache	B-Disease
suggests	O
a	O
direct	O
relationship	O
between	O
CGRP	B-Chemical
and	O
migraine	B-Disease
.	O

Coronary	B-Disease
aneurysm	I-Disease
after	O
implantation	O
of	O
a	O
paclitaxel	B-Chemical
-	O
eluting	O
stent	O
.	O

The	O
patient	O
was	O
asymptomatic	O
and	O
the	O
aneurysm	B-Disease
was	O
detected	O
in	O
a	O
routine	O
control	O
.	O

Behavioral	O
effects	O
of	O
urotensin-II	B-Chemical
centrally	O
administered	O
in	O
mice	O
.	O

v	O
.)	O
injection	O
of	O
U-II	B-Chemical
causes	O
hypertension	B-Disease
and	O
bradycardia	B-Disease
and	O
stimulates	O
prolactin	O
and	O
thyrotropin	O
secretion	O
.	O

However	O
,	O
the	O
behavioral	O
effects	O
of	O
centrally	O
administered	O
U-II	B-Chemical
have	O
received	O
little	O
attention	O
.	O

Administration	O
of	O
graded	O
doses	O
of	O
U-II	B-Chemical
(	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
mouse	O
)	O
provoked	O
:(	O
1	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
head	O
dips	O
in	O
the	O
hole	O
-	O
board	O
test	O
;(	O
2	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
white	O
chamber	O
in	O
the	O
black	O
-	O
and	O
-	O
white	O
compartment	O
test	O
,	O
and	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
central	O
platform	O
and	O
open	O
arms	O
in	O
the	O
plus	O
-	O
maze	O
test	O
;	O
and	O
(	O
3	O
)	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
in	O
the	O
forced	O
-	O
swimming	O
test	O
and	O
tail	O
suspension	O
test	O
.	O

Taken	O
together	O
,	O
the	O
present	O
study	O
demonstrates	O
that	O
the	O
central	O
injection	O
of	O
U-II	B-Chemical
at	O
doses	O
of	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
mouse	O
induces	O
anxiogenic	O
-	O
and	O
depressant	O
-	O
like	O
effects	O
in	O
mouse	O
.	O

These	O
data	O
suggest	O
that	O
U-II	B-Chemical
may	O
be	O
involved	O
in	O
some	O
aspects	O
of	O
psychiatric	B-Disease
disorders	I-Disease

We	O
report	O
the	O
case	O
of	O
a	O
woman	O
complaining	O
of	O
dysphonia	B-Disease
while	O
she	O
was	O
treated	O
by	O
acitretin	B-Chemical
.	O

Pharmacological	O
modulation	O
of	O
pain	B-Disease
-	O
related	O
brain	O
activity	O
during	O
normal	O
and	O
central	O
sensitization	O
states	O
in	O
humans	O
.	O

Abnormal	O
brain	O
responses	O
to	O
somatosensory	O
stimuli	O
have	O
been	O
found	O
in	O
patients	O
with	O
hyperalgesia	B-Disease
as	O
well	O
as	O
in	O
normal	O
subjects	O
during	O
experimental	O
central	O
sensitization	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
gabapentin	B-Chemical
,	O
a	O
drug	O
effective	O
in	O
neuropathic	B-Disease
pain	I-Disease
patients	O
,	O
on	O
brain	O
processing	O
of	O
nociceptive	O
information	O
in	O
normal	O
and	O
central	O
sensitization	O
states	O
.	O

The	O
dose	O
of	O
gabapentin	B-Chemical
was	O
1	O
,	O
800	O
mg	O
per	O
os	O
,	O
in	O
a	O
single	O
administration	O
.	O

These	O
findings	O
indicate	O
that	O
gabapentin	B-Chemical
has	O
a	O
measurable	O
antinociceptive	O
effect	O
and	O
a	O
stronger	O
antihyperalgesic	O
effect	O
most	O
evident	O
in	O
the	O
brain	O
areas	O
undergoing	O
deactivation	O
,	O
thus	O
supporting	O
the	O
concept	O
that	O
gabapentin	B-Chemical

MDMA	B-Chemical
polydrug	O
users	O
show	O
process	O
-	O
specific	O
central	O
executive	O
impairments	O
coupled	O
with	O
impaired	B-Disease
social	I-Disease
and	I-Disease
emotional	I-Disease
judgement	I-Disease
processes	I-Disease
.	O

These	O
data	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cognitive	O
processes	O
mediated	O
by	O
the	O
prefrontal	O
cortex	O
may	O
be	O
impaired	O
by	O
recreational	O
ecstasy	B-Chemical

Severe	O
citrate	B-Chemical
toxicity	B-Disease
complicating	O
volunteer	O
apheresis	O
platelet	O
donation	O
.	O

She	O
then	O
very	O
rapidly	O
developed	O
acute	O
onset	O
of	O
severe	O
facial	O
and	O
extremity	O
tetany	B-Disease
.	O

Empirical	O
treatment	O
with	O
intravenous	O
calcium	B-Chemical
gluconate	I-Chemical
was	O
initiated	O
,	O
and	O
muscle	B-Disease
contractions	I-Disease
slowly	O
subsided	O
over	O
approximately	O
10	O
to	O
15	O
minutes	O
.	O

Upon	O
additional	O
retrospective	O
analysis	O
,	O
it	O
was	O
noted	O
that	O
bumetanide	B-Chemical
is	O
a	O
loop	B-Chemical
diuretic	I-Chemical
that	O
may	O
cause	O
significant	O
hypocalcemia	B-Disease
.	O

Laboratory	O
measurement	O
of	O
pre	O
-	O
procedure	O
serum	O
calcium	B-Chemical

Proteinuria	B-Disease
after	O
conversion	O
to	O
sirolimus	B-Chemical
in	O
renal	O
transplant	O
recipients	O
.	O

We	O
retrospectively	O
examined	O
the	O
records	O
of	O
25	O
renal	O
transplant	O
patients	O
,	O
who	O
developed	O
or	O
displayed	O
increased	O
proteinuria	B-Disease
after	O
SRL	B-Chemical
conversion	O
.	O

Mean	O
follow	O
-	O
up	O
on	O
SRL	B-Chemical
therapy	O
was	O
20	O
+/-	O
12	O
(	O
6	O
to	O
43	O
)	O
months	O
.	O

001	O
).	O
Before	O
conversion	O
8	O
(	O
32	O
%)	O
patients	O
had	O
no	O
proteinuria	B-Disease
,	O
whereas	O
afterwards	O
all	O
patients	O
had	O
proteinuria	B-Disease
.	O

In	O
40	O
%	O
it	O
increased	O
by	O
more	O
than	O
100	O
%.	O
Twenty	O
-	O
eight	O
percent	O
of	O
patients	O
showed	O
increased	O
proteinuria	B-Disease
to	O
the	O
nephrotic	B-Disease
range	O
.	O

8	O
mg	O
/	O
dL	O
before	O
SRL	B-Chemical
therapy	O
and	O
2	O
.	O

Five	O
patients	O
displayed	O
CAN	B-Disease
and	O
Kaposi's	B-Disease
sarcoma	I-Disease
.	O

93	O
mg	O
/	O
dL	O
(	O
P	O
=.	O
02	O
).	O
Heavy	O
proteinuria	B-Disease
was	O
common	O
after	O
the	O
use	O
of	O
SRL	B-Chemical
as	O
rescue	O
therapy	O
for	O
renal	O
transplantation	O
.	O

The	O
possibility	O
of	O
de	O
novo	O
glomerular	O
pathology	O
under	O
SRL	B-Chemical

In	O
cyclophosphamide	B-Chemical
-	O
induced	O
cystitis	B-Disease
in	O
the	O
rat	O
,	O
detrusor	O
function	O
is	O
impaired	O
and	O
the	O
expression	O
and	O
effects	O
of	O
muscarinic	O
receptors	O
altered	O
.	O

Whether	O
or	O
not	O
the	O
neuronal	O
transmission	O
may	O
be	O
affected	O
by	O
cystitis	B-Disease
was	O
presently	O
investigated	O
.	O

Generally	O
,	O
atropine	B-Chemical
reduced	O
contractions	O
,	O
but	O
in	O
contrast	O
to	O
controls	O
,	O
it	O
also	O
reduced	O
responses	O
to	O
low	O
electrical	O
field	O
stimulation	O
intensity	O
(	O
1	O
-	O
5	O
Hz	O
)	O
in	O
inflamed	O
preparations	O
.	O

4-DAMP	B-Chemical
inhibited	O
the	O
tonic	O
contractions	O
in	O
controls	O
more	O
potently	O
than	O
methoctramine	B-Chemical
and	O
pirenzepine	B-Chemical
.	O

In	O
contrast	O
to	O
controls	O
,	O
methoctramine	B-Chemical
increased	O
--	O
instead	O
of	O
decreased	O
--	O
the	O
tonic	O
responses	O
at	O
high	O
frequencies	O
.	O

Associations	O
between	O
use	O
of	O
benzodiazepines	B-Chemical
or	O
related	O
drugs	O
and	O
health	O
,	O
physical	O
abilities	O
and	O
cognitive	O
function	O
:	O
a	O
non	O
-	O
randomised	O
clinical	O
study	O
in	O
the	O
elderly	O
.	O

Of	O
these	O
,	O
nearly	O
half	O
(	O
n	O
=	O
78	O
)	O
had	O
used	O
BZDs	B-Chemical
/	O
RDs	O
before	O
admission	O
,	O
and	O
the	O
remainder	O
(	O
n	O
=	O
86	O
)	O
were	O
non	O
-	O
users	O
.	O

The	O
residual	O
serum	O
concentrations	O
of	O
oxazepam	B-Chemical
,	O
temazepam	B-Chemical
and	O
zopiclone	B-Chemical
were	O
analysed	O
.	O

However	O
,	O
use	O
of	O
BZDs	B-Chemical
/	O
RDs	O
was	O
associated	O
with	O
dizziness	B-Disease
,	O
inability	B-Disease
to	I-Disease
sleep	I-Disease
after	O
awaking	O
at	O
night	O
and	O
tiredness	B-Disease
in	O
the	O
mornings	O
during	O
the	O
week	O
prior	O
to	O
admission	O
and	O
with	O
stronger	O
depressive	B-Disease
symptoms	I-Disease
measured	O
at	O
the	O
beginning	O
of	O
the	O
hospital	O
stay	O
.	O

Use	O
of	O
BZDs	B-Chemical
/	O
RDs	O
tended	O
to	O
be	O
associated	O
with	O
a	O
reduced	O
ability	O
to	O
walk	O
and	O
shorter	O
night	O
-	O
time	O
sleep	O
during	O
the	O
week	O
prior	O
to	O
admission	O
.	O

Acute	O
peripheral	B-Disease
neuropathy	I-Disease
caused	O
by	O
a	O
disulfiram	B-Chemical
overdose	B-Disease
is	O
very	O
rare	O
and	O
there	O
is	O
no	O
report	O
of	O
it	O
leading	O
to	O
vocal	B-Disease
fold	I-Disease
palsy	I-Disease
.	O

A	O
49	O
-	O
year	O
-	O
old	O
woman	O
was	O
transferred	O
to	O
our	O
department	O
because	O
of	O
quadriparesis	B-Disease
,	O
lancinating	O
pain	B-Disease
,	O
sensory	B-Disease
loss	I-Disease
,	O
and	O
paresthesia	B-Disease
of	O
the	O
distal	O
limbs	O
.	O

One	O
month	O
previously	O
,	O
she	O
had	O
taken	O
a	O
single	O
high	O
dose	O
of	O
disulfiram	B-Chemical
(	O
130	O
tablets	O
of	O
ALCOHOL	B-Chemical
STOP	O
TAB	O
,	O
Shin	O
-	O
Poong	O
Pharm	O
.	O

She	O
noticed	O
hoarseness	B-Disease
and	O
distally	O
accentuated	O
motor	O
and	O
sensory	O
dysfunction	O
after	O
she	O
had	O
recovered	O
from	O
this	O
state	O
.	O

Higher	O
optical	O
density	O
of	O
an	O
antigen	O
assay	O
predicts	O
thrombosis	B-Disease
in	O
patients	O
with	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Patients	O
with	O
more	O
than	O
50	O
%	O
decrease	O
in	O
platelet	O
count	O
or	O
thrombocytopenia	B-Disease
(<	O
150	O
x	O
10	O
(	O
9	O
)/	O
L	O
)	O
after	O
exposure	O
to	O
heparin	B-Chemical
,	O
who	O
had	O
a	O
positive	O
two	O
-	O
step	O
antigen	O
assay	O
[	O
optical	O
density	O
(	O
OD	O
)>	O
0	O
.	O

RESULTS	O
:	O
Forty	O
of	O
94	O
HIT	B-Disease
patients	O
had	O
thrombosis	B-Disease
at	O
diagnosis	O
;	O
54	O
/	O
94	O
had	O
isolated	O
-	O
HIT	B-Disease
without	O
thrombosis	B-Disease
.	O

At	O
diagnosis	O
there	O
was	O
no	O
significant	O
difference	O
in	O
OD	O
between	O
HIT	B-Disease
patients	O
with	O
thrombosis	B-Disease
and	O
those	O
with	O
isolated	O
-	O
HIT	B-Disease
.	O

89	O
),	O
including	O
isolated	O
-	O
HIT	B-Disease
patients	O
who	O
later	O
developed	O
thrombosis	B-Disease
within	O
30	O
d	O
(	O
n	O
=	O
8	O
,	O
1	O
.	O

27	O
in	O
the	O
isolated	O
-	O
HIT	B-Disease
group	O
had	O
a	O
significantly	O
higher	O
chance	O
of	O
developing	O
thrombosis	B-Disease
by	O
day	O
30	O
.	O

Similarly	O
,	O
thrombotic	B-Disease
risk	O
increased	O
with	O
age	O
and	O
OD	O
values	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
associated	O
with	O
clomiphene	B-Chemical
citrate	I-Chemical
(	O
CC	B-Chemical
).	O
DESIGN	O
:	O
Case	O
study	O
.	O

PATIENT	O
(	O
S	O
):	O
A	O
36	O
-	O
year	O
-	O
old	O
woman	O
referred	O
from	O
the	O
infertility	B-Disease
clinic	O
for	O
blurred	B-Disease
vision	I-Disease
.	O

INTERVENTION	O
(	O
S	O
):	O
Ophthalmic	O
examination	O
after	O
CC	B-Chemical
therapy	O
.	O

RESULT	O
(	O
S	O
):	O
A	O
36	O
-	O
year	O
-	O
old	O
Chinese	O
woman	O
developed	O
central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
after	O
eight	O
courses	O
of	O
CC	B-Chemical
.	O

CONCLUSION	O
(	O
S	O
):	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
after	O
treatment	O
with	O
CC	B-Chemical
.	O

Nicotine	B-Chemical
-	O
induced	O
nystagmus	B-Disease
correlates	O
with	O
midpontine	O
activation	O
.	O

NIN	B-Disease
correlated	O
with	O
blood	O
oxygen	B-Chemical
level	O
-	O
dependent	O
(	O
BOLD	O
)	O
activity	O
levels	O
in	O
a	O
midpontine	O
site	O
in	O
the	O
posterior	O
basis	O
pontis	O
.	O

NIN	B-Disease

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
role	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
mast	O
cell	O
histamine	B-Chemical
release	O
,	O
lipid	O
peroxide	O
(	O
LPO	O
)	O
generation	O
and	O
mucosal	O
microvascular	O
permeability	O
in	O
modulating	O
gastric	B-Disease
hemorrhage	I-Disease
and	O
ulcer	B-Disease
in	O
rats	O
with	O
atherosclerosis	B-Disease
induced	O
by	O
coadministration	O
of	O
vitamin	B-Chemical
D2	I-Chemical
and	O
cholesterol	B-Chemical
.	O

0	O
ml	O
/	O
kg	O
of	O
corn	O
oil	O
containing	O
vitamin	B-Chemical
D2	I-Chemical
and	O
cholesterol	B-Chemical
to	O
induce	O
atherosclerosis	B-Disease
.	O

Elevated	O
atherosclerotic	B-Disease
parameters	O
,	O
such	O
as	O
serum	O
calcium	B-Chemical
,	O
total	O
cholesterol	B-Chemical
and	O
low	O
-	O
density	O
lipoprotein	O
concentration	O
were	O
obtained	O
in	O
atherosclerotic	B-Disease
rats	O
.	O

Moreover	O
,	O
a	O
positive	O
correlation	O
of	O
histamine	B-Chemical
to	O
gastric	B-Disease
hemorrhage	I-Disease
and	O
to	O
ulcer	B-Disease
was	O
found	O
in	O
those	O
atherosclerotic	B-Disease
rats	O
.	O

Atherosclerosis	B-Disease
could	O
produce	O
gastric	B-Disease
hemorrhagic	I-Disease
ulcer	B-Disease
via	O
aggravation	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
LPO	O
generation	O
,	O
histamine	B-Chemical
release	O
and	O
microvascular	O
permeability	O
that	O
could	O
be	O
ameliorated	O
by	O
verapamil	B-Chemical

BACKGROUND	O
:	O
The	O
mechanisms	O
underlying	O
heart	B-Disease
failure	I-Disease
induced	O
by	O
adriamycin	B-Chemical
are	O
very	O
complicated	O
and	O
still	O
unclear	O
.	O

METHODS	O
:	O
3-methyladenine	B-Chemical
(	O
3MA	B-Chemical
),	O
a	O
specific	O
inhibitor	O
on	O
autophagy	O
was	O
used	O
in	O
a	O
heart	B-Disease
failure	I-Disease
model	O
of	O
rats	O
induced	O
by	O
adriamycin	B-Chemical
.	O

Neonatal	O
cardiomyocytes	O
were	O
isolated	O
from	O
Sprague	O
-	O
Dawley	O
rat	O
hearts	O
and	O
randomly	O
divided	O
into	O
controls	O
,	O
an	O
adriamycin	B-Chemical
-	O
treated	O
group	O
,	O
and	O
a	O
3MA	B-Chemical
plus	O
adriamycin	B-Chemical
-	O
treated	O
group	O
.	O

RESULTS	O
:	O
3MA	B-Chemical
significantly	O
improved	O
cardiac	O
function	O
and	O
reduced	O
mitochondrial	O
injury	O
.	O

Mitochondrial	O
injury	O
may	O
be	O
involved	O
in	O
the	O
progression	O
of	O
heart	B-Disease
failure	I-Disease
caused	O
by	O
adriamycin	B-Chemical

INTRODUCTION	O
:	O
Confusion	B-Disease
is	O
an	O
adverse	O
drug	O
reaction	O
frequently	O
observed	O
with	O
valproic	B-Chemical
acid	I-Chemical
.	O

RESULTS	O
:	O
272	O
cases	O
of	O
confusion	B-Disease
were	O
reported	O
with	O
valproic	B-Chemical
acid	I-Chemical
:	O
153	O
women	O
and	O
119	O
men	O
.	O

CONCLUSION	O
:	O
This	O
work	O
shows	O
that	O
confusion	B-Disease
with	O
valproic	B-Chemical
acid	I-Chemical

It	O
has	O
been	O
consistently	O
shown	O
that	O
ecstasy	B-Chemical
users	O
display	O
impairments	B-Disease
in	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
performance	O
.	O

In	O
addition	O
,	O
working	O
memory	O
processing	O
in	O
ecstasy	B-Chemical
users	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
neural	O
alterations	O
in	O
hippocampal	O
and	O
/	O
or	O
cortical	O
regions	O
as	O
measured	O
by	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
).	O
Using	O
functional	O
imaging	O
and	O
a	O
face	O
-	O
learning	O
task	O
,	O
we	O
investigated	O
neural	O
correlates	O
of	O
encoding	O
and	O
recalling	O
face	O
-	O
name	O
associations	O
in	O
20	O
recreational	O
drug	O
users	O
whose	O
predominant	O
drug	O
use	O
was	O
ecstasy	B-Chemical
and	O
20	O
controls	O
.	O

Neuroimage	O
40	O
,	O
1328	O
-	O
1339	O
).	O
Ecstasy	B-Chemical
users	O
performed	O
significantly	O
worse	O
in	O
learning	O
and	O
memory	O
compared	O
to	O
controls	O
and	O
cannabis	B-Chemical
users	O
.	O

A	O
conjunction	O
analysis	O
of	O
the	O
encode	O
and	O
recall	O
phases	O
of	O
the	O
task	O
revealed	O
ecstasy	B-Chemical
-	O
specific	O
hyperactivity	B-Disease
in	O
bilateral	O
frontal	O
regions	O
,	O
left	O
temporal	O
,	O
right	O
parietal	O
,	O
bilateral	O
temporal	O
,	O
and	O
bilateral	O
occipital	O
brain	O
regions	O
.	O

In	O
both	O
ecstasy	B-Chemical
and	O
cannabis	B-Chemical
groups	O
brain	O
activation	O
was	O
decreased	O
in	O
the	O
right	O
medial	O
frontal	O
gyrus	O
,	O
left	O
parahippocampal	O
gyrus	O
,	O
left	O
dorsal	O
cingulate	O
gyrus	O
,	O
and	O
left	O
caudate	O
.	O

Prolonged	O
elevation	O
of	O
plasma	O
argatroban	B-Chemical
in	O
a	O
cardiac	O
transplant	O
patient	O
with	O
a	O
suspected	O
history	O
of	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
with	O
thrombosis	B-Disease
.	O

The	O
patient	O
required	O
massive	O
transfusion	O
support	O
(	O
55	O
units	O
of	O
red	O
blood	O
cells	O
,	O
42	O
units	O
of	O
fresh	O
-	O
frozen	O
plasma	O
,	O
40	O
units	O
of	O
cryoprecipitate	O
,	O
40	O
units	O
of	O
platelets	O
,	O
and	O
three	O
doses	O
of	O
recombinant	O
Factor	O
VIIa	O
)	O
for	O
severe	O
intraoperative	B-Disease
and	I-Disease
postoperative	I-Disease
bleeding	I-Disease
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
Plasma	O
samples	O
from	O
before	O
and	O
after	O
CPB	O
were	O
analyzed	O
postoperatively	O
for	O
argatroban	B-Chemical
concentration	O
using	O
a	O
modified	O
ecarin	O
clotting	O
time	O
(	O
ECT	O
)	O
assay	O
.	O

RESULTS	O
:	O
Unexpectedly	O
high	O
concentrations	O
of	O
argatroban	B-Chemical
were	O
measured	O
in	O
these	O
samples	O
(	O
range	O
,	O
0	O
-	O
32	O
microg	O
/	O
mL	O
),	O
and	O
a	O
prolonged	O
plasma	O
argatroban	B-Chemical
half	O
life	O
(	O
t	O
(	O
1	O
/	O
2	O
))	O
of	O
514	O
minutes	O
was	O
observed	O
(	O
published	O
elimination	O
t	O
(	O
1	O
/	O
2	O
)	O
is	O
39	O
-	O
51	O
minutes	O
[<	O
or	O
=	O
181	O
minutes	O
with	O
hepatic	B-Disease
impairment	I-Disease
]).	O
CONCLUSIONS	O
:	O
Correlation	O
of	O
plasma	O
argatroban	B-Chemical
concentration	O
versus	O
the	O
patient	O
'	O
s	O
coagulation	O
variables	O
and	O
clinical	O
course	O
suggest	O
that	O
prolonged	O
elevated	O
levels	O
of	O
plasma	O
argatroban	B-Chemical
may	O
have	O
contributed	O
to	O
the	O
patient	O
'	O
s	O
extended	O
coagulopathy	B-Disease
.	O

Antituberculosis	B-Chemical
therapy	O
-	O
induced	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
:	O
magnitude	O
,	O
profile	O
,	O
prognosis	O
,	O
and	O
predictors	O
of	O
outcome	O
.	O

The	O
current	O
study	O
prospectively	O
evaluated	O
the	O
magnitude	O
,	O
clinical	O
course	O
,	O
outcome	O
,	O
and	O
prognostic	O
factors	O
in	O
ATT	O
-	O
ALF	B-Disease
.	O

2	O
%)	O
had	O
ATT	O
and	O
simultaneous	O
hepatitis	B-Disease
virus	I-Disease
infection	I-Disease
.	O

ATT	O
-	O
ALF	B-Disease
patients	O
were	O
younger	O
(	O
32	O
.	O

The	O
median	O
duration	O
of	O
ATT	O
before	O
ALF	B-Disease
was	O
30	O
(	O
7	O
-	O
350	O
)	O
days	O
.	O

Gastrointestinal	B-Disease
bleed	I-Disease
,	O
seizures	B-Disease
,	O
infection	B-Disease
,	O
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
were	O
documented	O
in	O
seven	O
(	O
10	O
%),	O
five	O
(	O
7	O
.	O

The	O
mortality	O
rate	O
among	O
patients	O
with	O
ATT	O
-	O
ALF	B-Disease
was	O
high	O
(	O
67	O
.	O

CONCLUSION	O
:	O
ATT	O
-	O
ALF	B-Disease
constituted	O
5	O
.	O

Central	B-Disease
nervous	I-Disease
system	I-Disease
complications	I-Disease
during	O
treatment	O
of	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
in	O
a	O
single	O
pediatric	O
institution	O
.	O

This	O
study	O
analyzed	O
the	O
incidence	O
of	O
neurological	B-Disease
complications	I-Disease
during	O
ALL	B-Disease
treatment	O
in	O
a	O
single	O
pediatric	O
institution	O
,	O
focusing	O
on	O
clinical	O
,	O
radiological	O
,	O
and	O
electrophysiological	O
findings	O
.	O

During	O
a	O
9	O
-	O
year	O
period	O
,	O
we	O
retrospectively	O
collected	O
27	O
neurological	O
events	O
(	O
11	O
%)	O
in	O
as	O
many	O
patients	O
,	O
from	O
253	O
children	O
enrolled	O
in	O
the	O
ALL	B-Disease
front	O
-	O
line	O
protocol	O
.	O

CNS	O
complications	O
included	O
posterior	O
reversible	O
leukoencephalopathy	B-Disease
syndrome	O
(	O
n	O
=	O
10	O
),	O
stroke	B-Disease
(	O
n	O
=	O
5	O
),	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
(	O
n	O
=	O
2	O
),	O
high	O
-	O
dose	O
methotrexate	B-Chemical
toxicity	B-Disease
(	O
n	O
=	O
2	O
),	O
syndrome	O
of	O
inappropriate	B-Disease
antidiuretic	I-Disease
hormone	I-Disease
secretion	I-Disease
(	O
n	O
=	O
1	O
),	O
and	O
other	O
unclassified	O
events	O
(	O
n	O
=	O
7	O
).	O
In	O
conclusion	O
,	O
CNS	O
complications	O
are	O
frequent	O
events	O
during	O
ALL	B-Disease

Safety	O
of	O
capecitabine	B-Chemical
:	O
a	O
review	O
.	O

WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
safety	O
of	O
capecitabine	B-Chemical
in	O
special	O
populations	O
such	O
as	O
patients	O
with	O
advanced	O
age	O
,	O
renal	B-Disease
and	I-Disease
kidney	I-Disease
disease	I-Disease
.	O

We	O
also	O
explore	O
different	O
dosing	O
and	O
schedules	O
of	O
capecitabine	B-Chemical
administration	O
.	O

Capecitabine	B-Chemical
has	O
a	O
well	O
-	O
established	O
safety	O
profile	O
and	O
can	O
be	O
given	O
safely	O
to	O
patients	O
with	O
advanced	O
age	O
,	O
hepatic	B-Disease
and	I-Disease
renal	I-Disease
dysfunctions	I-Disease

Previous	O
studies	O
have	O
indicated	O
that	O
the	O
globus	O
pallidus	O
receives	O
neurotensinergic	O
innervation	O
from	O
the	O
striatum	O
,	O
and	O
systemic	O
administration	O
of	O
a	O
neurotensin	B-Chemical
analog	O
could	O
produce	O
antiparkinsonian	O
effects	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
pallidal	O
neurotensin	B-Chemical
on	O
haloperidol	B-Chemical
-	O
induced	O
parkinsonian	B-Disease
symptoms	I-Disease
.	O

The	O
neurotensin	B-Chemical
type-1	I-Chemical
receptor	I-Chemical
antagonist	I-Chemical
SR48692	B-Chemical
blocked	O
both	O
the	O
behavioral	O
and	O
the	O
electrophysiological	O
effects	O
induced	O
by	O
neurotensin	B-Chemical
.	O

Antihypertensive	O
drugs	O
and	O
depression	B-Disease
:	O
a	O
reappraisal	O
.	O

The	O
results	O
showed	O
a	O
high	O
prevalence	O
of	O
depression	B-Disease
in	O
both	O
groups	O
of	O
patients	O
,	O
with	O
no	O
preponderance	O
in	O
the	O
hypertensive	B-Disease
group	O
.	O

This	O
was	O
accounted	O
for	O
by	O
a	O
significant	O
number	O
of	O
depressions	B-Disease
occurring	O
in	O
methyl	B-Chemical
dopa	I-Chemical
treated	O
patients	O
with	O
psychiatric	B-Disease

The	O
effects	O
of	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
on	O
cardiovascular	O
dynamics	O
and	O
pulmonary	O
shunt	O
(	O
QS	O
/	O
QT	O
)	O
were	O
investigated	O
in	O
12	O
dogs	O
before	O
and	O
during	O
sodium	B-Chemical
nitroprusside	I-Chemical
infusion	O
that	O
decreased	O
mean	O
arterial	O
blood	O
pressure	O
40	O
-	O
50	O
per	O
cent	O
.	O

Ten	O
cm	O
H2O	B-Chemical
CPAP	O
before	O
nitroprusside	B-Chemical
infusion	O
produced	O
a	O
further	O
decrease	B-Disease
in	I-Disease
arterial	I-Disease
blood	I-Disease
pressure	I-Disease
and	O
significantly	O
increased	O
heart	O
rate	O
and	O
decreased	B-Disease
cardiac	I-Disease
output	I-Disease
and	O
QS	O
/	O
QT	O
.	O

Five	O
cm	O
H2O	B-Chemical
CPAP	O
during	O
nitroprusside	B-Chemical
did	O
not	O
further	O
alter	O
any	O
of	O
the	O
above	O
-	O
mentioned	O
variables	O
.	O

These	O
data	O
indicate	O
that	O
nitroprusside	B-Chemical
infusion	O
rates	O
that	O
decrease	O
mean	O
arterial	O
blood	O
pressure	O
by	O
40	O
-	O
50	O
per	O
cent	O
do	O
not	O
change	O
cardiac	O
output	O
or	O
QS	O
/	O
QT	O
.	O

During	O
nitroprusside	B-Chemical
infusion	O
low	O
levels	O
of	O
CPAP	O
do	O
not	O
markedly	O
alter	O
cardiovascular	O
dynamics	O
,	O
but	O
high	O
levels	O
of	O
CPAP	O
(	O
10	O
cm	O
H2O	B-Chemical
),	O
while	O
decreasing	O
QS	O
/	O
QT	O
,	O
produce	O
marked	O
decreases	B-Disease
in	I-Disease
arterial	I-Disease
blood	I-Disease
pressure	I-Disease
and	I-Disease
cardiac	I-Disease
output	I-Disease

v	O
.)	O
decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
after	O
extracerebral	O
decarboxylase	O
inhibition	O
with	O
MK-486	B-Chemical
(	O
25	O
mg	O
/	O
kg	O
i	O
.	O

In	O
addition	O
,	O
reflex	O
bradycardia	B-Disease
caused	O
by	O
injected	O
norepinephrine	B-Chemical
was	O
significantly	O
enhanced	O
by	O
L-dopa	B-Chemical
,	O
DL-Threo-dihydroxyphenylserine	B-Chemical
had	O
no	O
effect	O
on	O
blood	O
pressure	O
,	O
heart	O
rate	O
or	O
reflex	O
responses	O
to	O
norepinephrine	B-Chemical
.	O

Pimozide	B-Chemical
did	O
not	O
affect	O
the	O
actions	O
of	O
L-dopa	B-Chemical
on	O
blood	O
pressure	O
and	O
heart	O
rate	O
but	O
completely	O
blocked	O
the	O
enhancement	O
of	O
reflexes	O
.	O

However	O
,	O
L-dopa	B-Chemical
restored	O
the	O
bradycardia	B-Disease
caused	O
by	O
norepinephrine	B-Chemical
in	O
addition	O
to	O
decreasing	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

5-HTP	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O

It	O
is	O
concluded	O
that	O
L-dopa	B-Chemical
enhances	O
reflex	O
bradycardia	B-Disease
through	O
central	O
alpha	O
-	O
receptor	O
stimulation	O
.	O

Clinical	O
and	O
experimental	O
data	O
published	O
to	O
date	O
suggest	O
several	O
possible	O
mechanisms	O
by	O
which	O
cocaine	B-Chemical
may	O
result	O
in	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
.	O

In	O
other	O
individuals	O
with	O
no	O
underlying	O
atherosclerotic	B-Disease
obstruction	I-Disease
,	O
coronary	B-Disease
occlusion	I-Disease
may	O
be	O
due	O
to	O
spasm	B-Disease
,	O
thrombus	B-Disease
,	O
or	O
both	O
.	O

With	O
regard	O
to	O
spasm	B-Disease
,	O
the	O
clinical	O
findings	O
are	O
largely	O
circumstantial	O
,	O
and	O
the	O
locus	O
of	O
cocaine	B-Chemical
-	O
induced	O
vasoconstriction	O
remains	O
speculative	O
.	O

Diffuse	O
intramural	O
vasoconstriction	O
is	O
not	O
consistent	O
with	O
reports	O
of	O
segmental	O
,	O
discrete	O
infarction	B-Disease
.	O

The	O
finding	O
of	O
cocaine	B-Chemical
-	O
induced	O
vasoconstriction	O
in	O
segments	O
of	O
(	O
noninnervated	O
)	O
human	O
umbilical	O
artery	O
suggests	O
that	O
the	O
presence	O
or	O
absence	O
of	O
intact	O
innervation	O
is	O
not	O
sufficient	O
to	O
explain	O
the	O
discrepant	O
data	O
involving	O
the	O
possibility	O
of	O
alpha	O
-	O
mediated	O
effects	O
.	O

Rabbit	B-Disease
syndrome	I-Disease
,	O
antidepressant	B-Chemical
use	O
,	O
and	O
cerebral	O
perfusion	O
SPECT	O
scan	O
findings	O
.	O

Repeated	O
cerebral	O
perfusion	O
SPECT	O
scans	O
revealed	O
decreased	B-Disease
basal	I-Disease
ganglia	I-Disease
perfusion	I-Disease
while	O
the	O
movement	B-Disease
disorder	I-Disease
was	O
present	O
,	O
and	O
a	O
return	O
to	O
normal	O
perfusion	O
when	O
the	O
rabbit	B-Disease
syndrome	I-Disease

The	O
bronchodilator	O
effects	O
of	O
a	O
single	O
dose	O
of	O
ipratropium	B-Chemical
bromide	I-Chemical
aerosol	O
(	O
36	O
micrograms	O
)	O
and	O
short	O
-	O
acting	O
theophylline	B-Chemical
tablets	O
(	O
dose	O
titrated	O
to	O
produce	O
serum	O
levels	O
of	O
10	O
-	O
20	O
micrograms	O
/	O
mL	O
)	O
were	O
compared	O
in	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
crossover	O
study	O
in	O
21	O
patients	O
with	O
stable	O
,	O
chronic	B-Disease
obstructive	I-Disease
pulmonary	I-Disease
disease	I-Disease
.	O

Mean	O
peak	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
increases	O
over	O
baseline	O
and	O
the	O
proportion	O
of	O
patients	O
attaining	O
at	O
least	O
a	O
15	O
%	O
increase	O
in	O
the	O
FEV1	O
(	O
responders	O
)	O
were	O
31	O
%	O
and	O
90	O
%,	O
respectively	O
,	O
for	O
ipratropium	B-Chemical
and	O
17	O
%	O
and	O
50	O
%,	O
respectively	O
,	O
for	O
theophylline	B-Chemical
.	O

8	O
hours	O
with	O
ipratropium	B-Chemical
and	O
2	O
.	O

These	O
results	O
show	O
that	O
ipratropium	B-Chemical
is	O
a	O
more	O
potent	O
bronchodilator	O
than	O
oral	O
theophylline	B-Chemical
in	O
patients	O
with	O
chronic	B-Disease
airflow	I-Disease
obstruction	I-Disease

This	O
study	O
shows	O
that	O
prolonged	O
analgesic	O
treatment	O
in	O
Fischer	O
344	O
rats	O
causes	O
progressive	O
and	O
irreversible	O
damage	O
to	O
the	O
interstitial	O
matrix	O
and	O
type	O
1	O
interstitial	O
cells	O
leading	O
to	O
RPN	B-Disease

Less	O
frequent	O
lithium	B-Chemical
administration	O
and	O
lower	O
urine	O
volume	O
.	O

METHOD	O
:	O
This	O
was	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
85	O
patients	O
from	O
a	O
lithium	B-Chemical
clinic	O
who	O
received	O
different	O
dose	O
schedules	O
.	O

RESULTS	O
:	O
Multiple	O
daily	O
doses	O
of	O
lithium	B-Chemical
were	O
associated	O
with	O
higher	O
urine	O
volumes	O
.	O

CONCLUSIONS	O
:	O
Urine	O
volume	O
can	O
be	O
reduced	O
by	O
giving	O
lithium	B-Chemical
once	O
daily	O
and	O
/	O
or	O
by	O
lowering	O
the	O
total	O
daily	O
dose	O
.	O

Lithium	B-Chemical
-	O
induced	O
polyuria	B-Disease

Thermal	O
enhancement	O
of	O
Adriamycin	B-Chemical
-	O
mediated	O
antitumor	O
activity	O
and	O
normal	O
tissue	O
toxicities	B-Disease
by	O
whole	O
body	O
hyperthermia	B-Disease
were	O
compared	O
using	O
a	O
F344	O
rat	O
model	O
.	O

Acute	O
normal	O
tissue	O
toxicities	B-Disease
(	O
i	O
.	O

e	O
.,	O
myocardial	B-Disease
and	I-Disease
kidney	I-Disease
injury	I-Disease
)	O
were	O
evaluated	O
by	O
functional	O
/	O
physiological	O
assays	O
and	O
by	O
morphological	O
techniques	O
.	O

3	O
,	O
whereas	O
those	O
estimated	O
for	O
"	O
late	O
"	O
damage	O
(	O
based	O
on	O
morphological	O
cardiac	B-Disease
and	I-Disease
renal	I-Disease
lesions	I-Disease
)	O
varied	O
between	O
2	O
.	O

Prazosin	B-Chemical
-	O
induced	O
stress	B-Disease
incontinence	I-Disease
.	O

Prazosin	B-Chemical
exerts	O
its	O
antihypertensive	O
effects	O
through	O
vasodilatation	O
caused	O
by	O
selective	O
blockade	O
of	O
postsynaptic	O
alpha	O
-	O
1	O
adrenergic	O
receptors	O
.	O

Patients	O
who	O
present	O
with	O
stress	B-Disease
incontinence	I-Disease
while	O
taking	O
prazosin	B-Chemical
should	O
change	O
their	O
antihypertensive	O
medication	O
before	O
considering	O
surgery	O
,	O
because	O
their	O
incontinence	B-Disease

A	O
78	O
-	O
year	O
-	O
old	O
with	O
healed	O
septal	O
necrosis	B-Disease
suffered	O
a	O
recurrent	O
myocardial	B-Disease
infarction	I-Disease
of	O
the	O
anterior	O
wall	O
following	O
the	O
administration	O
of	O
isosorbide	B-Chemical
dinitrate	I-Chemical
5	O
mg	O
sublingually	O
.	O

After	O
detailing	O
the	O
course	O
of	O
events	O
,	O
we	O
discuss	O
the	O
role	O
of	O
paradoxical	O
coronary	O
spasm	B-Disease
and	O
hypotension	B-Disease
-	O
mediated	O
myocardial	B-Disease
ischemia	I-Disease
occurring	O
downstream	O
to	O
significant	O
coronary	B-Disease
arterial	I-Disease
stenosis	I-Disease
in	O
the	O
pathophysiology	O
of	O
acute	B-Disease
coronary	I-Disease
insufficiency	I-Disease

Five	O
patients	O
receiving	O
fluoxetine	B-Chemical
for	O
the	O
treatment	O
of	O
obsessive	B-Disease
compulsive	I-Disease
disorder	I-Disease
or	O
major	B-Disease
depression	I-Disease
developed	O
akathisia	B-Disease
.	O

Three	O
patients	O
who	O
had	O
experienced	O
neuroleptic	O
-	O
induced	O
akathisia	B-Disease
in	O
the	O
past	O
reported	O
that	O
the	O
symptoms	O
of	O
fluoxetine	B-Chemical
-	O
induced	O
akathisia	B-Disease
were	O
identical	O
,	O
although	O
somewhat	O
milder	O
.	O

The	O
authors	O
suggest	O
that	O
fluoxetine	B-Chemical
-	O
induced	O
akathisia	B-Disease
may	O
be	O
caused	O
by	O
serotonergically	O
mediated	O
inhibition	O
of	O
dopaminergic	O
neurotransmission	O
and	O
that	O
the	O
pathophysiology	O
of	O
fluoxetine	B-Chemical
-	O
induced	O
akathisia	B-Disease
and	O
tricyclic	O
antidepressant	B-Chemical

Diclofenac	B-Chemical
sodium	I-Chemical
(	O
Voltarol	B-Chemical
,	O
Geigy	O
Pharmaceuticals	O
)	O
is	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
derivative	O
of	O
phenylacetic	B-Chemical
acid	I-Chemical
.	O

Although	O
generally	O
well	O
-	O
tolerated	O
,	O
asymptomatic	O
abnormalities	B-Disease
of	I-Disease
liver	I-Disease
function	I-Disease
have	O
been	O
recorded	O
and	O
,	O
less	O
commonly	O
,	O
severe	O
hepatitis	B-Disease
induced	O
by	O
diclofenac	B-Chemical
.	O

Stroke	B-Disease
associated	O
with	O
cocaine	B-Chemical
use	O
.	O

Stroke	B-Disease
followed	O
cocaine	B-Chemical
use	O
by	O
inhalation	O
,	O
intranasal	O
,	O
intravenous	O
,	O
and	O
intramuscular	O
routes	O
.	O

Glyburide	B-Chemical
-	O
induced	O
hepatitis	B-Disease
.	O

For	O
glyburide	B-Chemical
,	O
a	O
second	O
-	O
generation	O
sulfonylurea	B-Chemical
,	O
only	O
two	O
brief	O
reports	O
of	O
hepatotoxicity	B-Disease
exist	O
.	O

There	O
was	O
no	O
serologic	O
evidence	O
of	O
viral	B-Disease
infection	I-Disease
,	O
and	O
a	O
liver	O
biopsy	O
sample	O
showed	O
a	O
histologic	O
pattern	O
consistent	O
with	O
drug-induced	B-Disease
hepatitis	I-Disease
.	O

Glyburide	B-Chemical
can	O
produce	O
an	O
acute	B-Disease
hepatitis-like	I-Disease
illness	I-Disease

Mean	O
arterial	O
pressure	O
was	O
decreased	O
to	O
50	O
mm	O
Hg	O
for	O
30	O
minutes	O
either	O
by	O
hemorrhage	B-Disease
(	O
HEM	B-Disease
,	O
n	O
=	O
7	O
)	O
or	O
by	O
continuous	O
infusion	O
of	O
sodium	B-Chemical
nitroprusside	I-Chemical
(	O
SNP	B-Chemical
,	O
n	O
=	O
7	O
).	O
During	O
HEM	B-Disease
-	O
induced	O
hypotension	B-Disease
the	O
cardiac	O
output	O
was	O
significantly	O
lower	O
and	O
systemic	O
vascular	O
resistance	O
higher	O
compared	O
with	O
that	O
in	O
the	O
SNP	B-Chemical
group	O
.	O

The	O
SPV	O
during	O
hypotension	B-Disease
was	O
15	O
.	O

0	O
mm	O
Hg	O
in	O
the	O
SNP	B-Chemical
group	O
(	O
P	O
less	O
than	O
0	O
.	O

02	O
).	O
It	O
is	O
concluded	O
that	O
increases	O
in	O
the	O
SPV	O
and	O
the	O
delta	O
down	O
are	O
characteristic	O
of	O
a	O
hypotensive	B-Disease
state	O
due	O
to	O
a	O
predominant	O
decrease	O
in	O
preload	O
.	O

Drug	O
-	O
induced	O
arterial	O
spasm	B-Disease
relieved	O
by	O
lidocaine	B-Chemical
.	O

Intense	O
vasospasm	B-Disease
with	O
threatened	O
gangrene	B-Disease
arose	O
in	O
the	O
arm	O
used	O
for	O
the	O
infusion	O
.	O

Since	O
the	O
cranial	O
condition	O
precluded	O
use	O
of	O
more	O
usual	O
methods	O
,	O
lidocaine	B-Chemical
was	O
given	O
intra	O
-	O
arterially	O
,	O
with	O
careful	O
cardiovascular	O
monitoring	O
,	O
to	O
counteract	O
the	O
vasospasm	B-Disease

Cerebral	O
blood	O
flow	O
and	O
cerebral	O
metabolic	O
rate	O
for	O
oxygen	B-Chemical
were	O
measured	O
during	O
isoflurane	B-Chemical
-	O
induced	O
hypotension	B-Disease
in	O
10	O
patients	O
subjected	O
to	O
craniotomy	O
for	O
clipping	O
of	O
a	O
cerebral	B-Disease
aneurysm	I-Disease
.	O

75	O
%(	O
plus	O
67	O
%	O
nitrous	B-Chemical
oxide	I-Chemical
in	O
oxygen	B-Chemical
),	O
during	O
which	O
CBF	O
and	O
CMRO2	O
were	O
34	O
.	O

1	O
kPa	O
(	O
mean	O
+/-	O
SEM	O
).	O
Controlled	O
hypotension	B-Disease
to	O
an	O
average	O
MAP	O
of	O
50	O
-	O
55	O
mm	O
Hg	B-Chemical
was	O
induced	O
by	O
increasing	O
the	O
dose	O
of	O
isoflurane	B-Chemical
,	O
and	O
maintained	O
at	O
an	O
inspired	O
concentration	O
of	O
2	O
.	O

These	O
changes	O
might	O
offer	O
protection	O
to	O
brain	O
tissue	O
during	O
periods	O
of	O
induced	O
hypotension	B-Disease

Allergic	B-Disease
reaction	I-Disease
to	O
5-fluorouracil	B-Chemical
infusion	O
.	O

Oral	O
diphenhydramine	B-Chemical
and	O
prednisone	B-Chemical
were	O
ineffective	O
in	O
preventing	O
the	O
recurrence	O
of	O
the	O
allergic	B-Disease
reaction	I-Disease

We	O
observed	O
sinoatrial	B-Disease
block	I-Disease
due	O
to	O
chronic	O
amiodarone	B-Chemical
administration	O
in	O
a	O
5	O
-	O
year	O
-	O
old	O
boy	O
with	O
primary	B-Disease
cardiomyopathy	I-Disease
,	O
Wolff-Parkinson-White	B-Disease
syndrome	I-Disease
and	O
supraventricular	B-Disease
tachycardia	I-Disease
.	O

Three	O
infants	O
,	O
born	O
of	O
two	O
mothers	O
with	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
who	O
received	O
treatment	O
with	O
sulphasalazine	B-Chemical
throughout	O
pregnancy	O
,	O
were	O
found	O
to	O
have	O
major	O
congenital	B-Disease
anomalies	I-Disease
.	O

In	O
the	O
twin	O
pregnancy	O
,	O
the	O
mother	O
had	O
Crohn's	B-Disease
disease	I-Disease
.	O

The	O
second	O
twin	O
,	O
a	O
male	O
,	O
had	O
some	O
features	O
of	O
Potter's	B-Disease
facies	I-Disease
,	O
hypoplastic	B-Disease
lungs	I-Disease
,	O
absent	B-Disease
kidneys	I-Disease
and	I-Disease
ureters	I-Disease
,	O
and	O
talipes	B-Disease
equinovarus	I-Disease
.	O

Despite	O
reports	O
to	O
the	O
contrary	O
,	O
it	O
is	O
suggested	O
that	O
sulphasalazine	B-Chemical

A	O
case	O
of	O
veno-occlusive	B-Disease
disease	I-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
with	O
fatal	O
outcome	O
after	O
dacarbazine	B-Chemical
(	O
DTIC	B-Chemical
)	O
therapy	O
for	O
melanoma	B-Disease
is	O
reported	O
.	O

At	O
autopsy	O
the	O
liver	O
was	O
enlarged	O
and	O
firm	O
with	O
signs	O
of	O
venous	B-Disease
congestion	I-Disease
.	O

Abnormal	B-Disease
involuntary	I-Disease
movements	I-Disease
appeared	O
in	O
the	O
mouth	O
,	O
tongue	O
,	O
neck	O
and	O
abdomen	O
of	O
a	O
64	O
-	O
year	O
-	O
old	O
male	O
patient	O
after	O
he	O
took	O
metoclopramide	B-Chemical
for	O
gastrointestinal	B-Disease
disorder	I-Disease
in	O
a	O
regimen	O
of	O
30	O
mg	O
per	O
day	O
for	O
a	O
total	O
of	O
about	O
260	O
days	O
.	O

Attention	O
to	O
the	O
possible	O
induction	O
of	O
specific	O
tardive	B-Disease
dyskinesia	I-Disease

A	O
case	O
is	O
presented	O
of	O
a	O
reversible	O
intra-Hisian	B-Disease
block	I-Disease
occurring	O
under	O
amiodarone	B-Chemical
treatment	O
for	O
atrial	B-Disease
tachycardia	I-Disease
in	O
a	O
patient	O
without	O
clear	O
intraventricular	B-Disease
conduction	I-Disease
abnormalities	I-Disease
.	O

Amiodarone	B-Chemical

Busulfan	B-Chemical
-	O
induced	O
hemorrhagic	B-Disease
cystitis	I-Disease
.	O

The	O
similarity	O
between	O
the	O
histologic	O
appearances	O
of	O
busulfan	B-Chemical
cystitis	B-Disease
and	O
both	O
radiation	O
and	O
cyclophosphamide	B-Chemical
-	O
induced	O
cystitis	B-Disease
is	O
discussed	O
and	O
the	O
world	O
literature	O
reviewed	O
.	O

Rebound	O
hypertensive	B-Disease
after	O
sodium	B-Chemical
nitroprusside	I-Chemical
prevented	O
by	O
saralasin	B-Chemical
in	O
rats	O
.	O

A	O
second	O
group	O
of	O
rats	O
was	O
treated	O
identically	O
and	O
,	O
in	O
addition	O
,	O
received	O
an	O
infusion	O
of	O
saralasin	B-Chemical
(	O
a	O
competitive	O
inhibitor	O
of	O
angiotensin	B-Chemical
II	I-Chemical
)	O
throughout	O
the	O
experimental	O
period	O
.	O

During	O
the	O
SNP	B-Chemical
infusion	O
the	O
control	O
animals	O
demonstrated	O
a	O
progressive	O
increase	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
to	O
61	O
torr	O
,	O
whereas	O
the	O
saralasin	B-Chemical
-	O
treated	O
animals	O
showed	O
no	O
change	O
.	O

Following	O
discontinuation	O
of	O
SNP	B-Chemical
,	O
blood	O
pressure	O
in	O
the	O
control	O
animals	O
rebounded	O
to	O
94	O
torr	O
,	O
as	O
compared	O
with	O
78	O
torr	O
in	O
the	O
saralasin	B-Chemical
-	O
treated	O
rats	O
.	O

Toxic	B-Disease
hepatitis	I-Disease
induced	O
by	O
antithyroid	O
drugs	O
:	O
four	O
cases	O
including	O
one	O
with	O
cross	O
-	O
reactivity	O
between	O
carbimazole	B-Chemical
and	O
benzylthiouracil	B-Chemical
.	O

METHODS	O
:	O
Retrospective	O
review	O
of	O
medical	O
records	O
of	O
236	O
patients	O
with	O
hyperthyroidism	B-Disease
admitted	O
in	O
our	O
department	O
(	O
in	O
-	O
or	O
out	O
-	O
patients	O
)	O
from	O
1986	O
to	O
1992	O
.	O

One	O
of	O
the	O
latter	O
two	O
patients	O
further	O
experienced	O
a	O
cytolytic	O
hepatitis	B-Disease
which	O
appeared	O
after	O
Benzylthiouracil	B-Chemical
(	O
Basd	B-Chemical
ne	I-Chemical
)	O
had	O
replaced	O
carbimazole	B-Chemical
.	O

Biological	O
features	O
of	O
hepatitis	B-Disease
disappeared	O
in	O
all	O
cases	O
after	O
cessation	O
of	O
the	O
incriminated	O
drug	O
,	O
while	O
biliary	O
,	O
viral	O
and	O
immunological	O
searches	O
were	O
negative	O
.	O

CONCLUSION	O
:	O
Toxic	B-Disease
hepatitis	I-Disease
is	O
a	O
potential	O
adverse	O
effect	O
of	O
antithyroid	O
drugs	O
which	O
warrants	O
,	O
as	O
for	O
haematological	O
disturbances	O
,	O
a	O
pre	O
-	O
therapeutic	O
determination	O
and	O
a	O
careful	O
follow	O
-	O
up	O
of	O
relevant	O
biological	O
markers	O
.	O

A	O
prospective	O
,	O
randomized	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
role	O
of	O
vitamin	B-Chemical
B12	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
supplementation	O
in	O
preventing	O
zidovudine	B-Chemical
(	O
ZDV	B-Chemical
)-	O
induced	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
.	O

During	O
the	O
study	O
,	O
vitamin	B-Chemical
B12	I-Chemical
and	O
folate	B-Chemical
levels	O
were	O
significantly	O
higher	O
in	O
group	O
II	O
patients	O
;	O
however	O
,	O
no	O
differences	O
in	O
hemoglobin	O
,	O
hematocrit	O
,	O
mean	O
corpuscular	O
volume	O
,	O
and	O
white	O
-	O
cell	O
,	O
neutrophil	O
and	O
platelet	O
counts	O
were	O
observed	O
between	O
groups	O
at	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
.	O

Severe	O
hematologic	O
toxicity	B-Disease
(	O
neutrophil	O
count	O
<	O
1000	O
/	O
mm3	O
and	O
/	O
or	O
hemoglobin	O
<	O
8	O
g	O
/	O
dl	O
)	O
occurred	O
in	O
4	O
patients	O
assigned	O
to	O
group	O
I	O
and	O
7	O
assigned	O
to	O
group	O
II	O
.	O

There	O
was	O
no	O
correlation	O
between	O
vitamin	B-Chemical
B12	I-Chemical
or	O
folate	B-Chemical
levels	O
and	O
development	O
of	O
myelosuppression	B-Disease
.	O

Acute	O
confusion	B-Disease
induced	O
by	O
a	O
high	O
-	O
dose	O
infusion	O
of	O
5-fluorouracil	B-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
.	O

He	O
developed	O
acute	O
neurologic	O
symptoms	O
of	O
mental	O
confusion	B-Disease
,	O
disorientation	B-Disease
and	O
irritability	B-Disease
,	O
and	O
then	O
lapsed	O
into	O
a	O
deep	O
coma	B-Disease
,	O
lasting	O
for	O
approximately	O
40	O
hours	O
during	O
the	O
first	O
dose	O
(	O
day	O
2	O
)	O
of	O
5-fluorouracil	B-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
infusion	O
.	O

The	O
pathogenesis	O
of	O
5-fluorouracil	B-Chemical
neurotoxicity	B-Disease
may	O
be	O
due	O
to	O
a	O
Krebs	O
cycle	O
blockade	O
by	O
fluoroacetate	B-Chemical
and	O
fluorocitrate	B-Chemical
,	O
thiamine	B-Chemical
deficiency	O
,	O
or	O
dihydrouracil	B-Chemical
dehydrogenase	O
deficiency	O
.	O

Effect	O
of	O
switching	O
carbamazepine	B-Chemical
to	O
oxcarbazepine	B-Chemical
on	O
the	O
plasma	O
levels	O
of	O
neuroleptics	O
.	O

Carbamazepine	B-Chemical
was	O
switched	O
to	O
its	O
10	O
-	O
keto	O
analogue	O
oxcarbazepine	B-Chemical
among	O
six	O
difficult	O
-	O
to	O
-	O
treat	O
schizophrenic	B-Disease
or	O
organic	B-Disease
psychotic	I-Disease
patients	O
using	O
concomitantly	O
haloperidol	B-Chemical
,	O
chlorpromazine	B-Chemical
or	O
clozapine	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
erythema	B-Disease
multiforme	I-Disease
and	O
hypersensitivity	B-Disease
myocarditis	I-Disease
caused	O
by	O
ampicillin	B-Chemical
.	O

Medications	O
were	O
discontinued	O
when	O
erythema	B-Disease
multiforme	I-Disease
and	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
caused	O
by	O
myocarditis	B-Disease
occurred	O
.	O

The	O
patient	O
was	O
treated	O
with	O
methylprednisolone	B-Chemical
and	O
gradually	O
improved	O
.	O

Positive	O
MIF	O
test	O
for	O
ampicillin	B-Chemical
showed	O
sensitization	O
of	O
the	O
patient	O
'	O
s	O
lymphocytes	O
to	O
ampicillin	B-Chemical
.	O

CONCLUSIONS	O
:	O
Hypersensitivity	B-Disease
myocarditis	I-Disease
is	O
a	O
rare	O
and	O
dangerous	O
manifestation	O
of	O
allergy	B-Disease
to	O
penicillins	B-Chemical

A	O
large	O
group	O
of	O
patients	O
with	O
suspected	O
allergic	B-Disease
reactions	I-Disease
to	O
beta-lactam	B-Chemical
antibiotics	O
was	O
evaluated	O
.	O

RAST	O
for	O
BPO-PLL	B-Chemical
and	O
AX	B-Chemical
-	O
PLL	O
was	O
done	O
.	O

A	O
total	O
of	O
177	O
patients	O
were	O
diagnosed	O
as	O
allergic	B-Disease
to	O
beta-lactam	B-Chemical
antibiotics	O
.	O

Anaphylaxis	B-Disease
was	O
seen	O
in	O
37	O
patients	O
(	O
69	O
%),	O
the	O
other	O
17	O
(	O
31	O
%)	O
having	O
urticaria	B-Disease
and	O
/	O
or	O
angioedema	B-Disease
.	O

All	O
the	O
patients	O
were	O
skin	O
test	O
negative	O
to	O
BPO	B-Chemical
;	O
49	O
of	O
51	O
(	O
96	O
%)	O
were	O
also	O
negative	O
to	O
MDM	B-Disease
,	O
and	O
44	O
of	O
46	O
(	O
96	O
%)	O
to	O
PG	B-Chemical
.	O

Skin	O
tests	O
with	O
AX	B-Chemical
were	O
positive	O
in	O
34	O
(	O
63	O
%)	O
patients	O
.	O

PG	B-Chemical
was	O
well	O
tolerated	O
by	O
all	O
54	O
patients	O
.	O

We	O
describe	O
the	O
largest	O
group	O
of	O
AX	B-Chemical
-	O
allergic	B-Disease
patients	O
who	O
have	O
tolerated	O
PG	B-Chemical
reported	O
so	O
far	O
.	O

Reports	O
of	O
persistent	O
paralysis	B-Disease
after	O
the	O
discontinuance	O
of	O
these	O
drugs	O
have	O
most	O
often	O
involved	O
aminosteroid	O
-	O
based	O
NMBAs	O
such	O
as	O
vecuronium	B-Chemical
bromide	I-Chemical
,	O
especially	O
when	O
used	O
in	O
conjunction	O
with	O
corticosteroids	O
.	O

We	O
report	O
a	O
case	O
of	O
atracurium	B-Chemical
-	O
related	O
paralysis	B-Disease

Six	O
epidemiologic	O
studies	O
in	O
the	O
United	O
States	O
and	O
Europe	O
indicate	O
that	O
habitual	O
use	O
of	O
phenacetin	B-Chemical
is	O
associated	O
with	O
the	O
development	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
and	O
end-stage	B-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
),	O
with	O
a	O
relative	O
risk	O
in	O
the	O
range	O
of	O
4	O
to	O
19	O
.	O

As	O
a	O
result	O
of	O
these	O
and	O
other	O
studies	O
,	O
phenacetin	B-Chemical
has	O
now	O
been	O
withdrawn	O
from	O
the	O
market	O
in	O
most	O
countries	O
.	O

These	O
studies	O
suggest	O
that	O
both	O
phenacetin	B-Chemical
and	O
acetaminophen	B-Chemical
may	O
contribute	O
to	O
the	O
burden	O
of	O
ESRD	B-Disease
,	O
with	O
the	O
risk	O
of	O
the	O
latter	O
being	O
somewhat	O
less	O
than	O
that	O
of	O
the	O
former	O
.	O

Thus	O
,	O
acetaminophen	B-Chemical
has	O
been	O
used	O
both	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
with	O
other	O
analgesics	O
,	O
whereas	O
phenacetin	B-Chemical
was	O
available	O
only	O
in	O
combinations	O
.	O

Reduction	O
of	O
heparan	B-Chemical
sulphate	I-Chemical
-	O
associated	O
anionic	O
sites	O
in	O
the	O
glomerular	O
basement	O
membrane	O
of	O
rats	O
with	O
streptozotocin	B-Chemical
-	O
induced	O
diabetic	B-Disease
nephropathy	I-Disease
.	O

The	O
majority	O
of	O
anionic	O
sites	O
(	O
74	O
%	O
in	O
diabetic	B-Disease
and	O
81	O
%	O
in	O
control	O
rats	O
)	O
were	O
found	O
within	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
.	O

002	O
).	O
At	O
the	O
same	O
time	O
,	O
the	O
number	O
of	O
heparan	B-Chemical
sulphate	I-Chemical
anionic	O
sites	O
and	O
the	O
total	O
anionic	O
site	O
surface	O
(	O
number	O
of	O
anionic	O
sites	O
x	O
mean	O
anionic	O
site	O
surface	O
)	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
was	O
reduced	O
by	O
19	O
%(	O
p	O
<	O
0	O
.	O

We	O
conclude	O
that	O
in	O
streptozotocin	B-Chemical
-	O
diabetic	B-Disease
rats	O
with	O
an	O
increased	O
urinary	O
albumin	O
excretion	O
,	O
a	O
reduced	O
heparan	B-Chemical
sulphate	I-Chemical

Effect	O
of	O
some	O
anticancer	O
drugs	O
and	O
combined	O
chemotherapy	O
on	O
renal	B-Disease
toxicity	I-Disease
.	O

After	O
MTX	B-Chemical
administration	O
a	O
significant	O
increase	O
(	O
p	O
=	O
0	O
.	O

0001	O
)	O
decrease	O
in	O
creatinine	B-Chemical
clearance	O
was	O
noted	O
compared	O
to	O
controls	O
.	O

0343	O
)	O
in	O
creatinine	B-Chemical
clearance	O
was	O
found	O
,	O
but	O
creatinine	B-Chemical
concentration	O
did	O
not	O
increase	O
significantly	O
compared	O
to	O
controls	O
.	O

CY	B-Chemical
caused	O
hemorrhagic	B-Disease
cystitis	I-Disease
in	O
40	O
%	O
of	O
rats	O
,	O
but	O
it	O
did	O
not	O
cause	O
this	O
complication	O
when	O
combined	O
with	O
5-FU	B-Chemical
and	O
MTX	B-Chemical
.	O

Lithium	B-Chemical
-	O
associated	O
cognitive	B-Disease
and	I-Disease
functional	I-Disease
deficits	I-Disease
reduced	O
by	O
a	O
switch	O
to	O
divalproex	B-Chemical
sodium	I-Chemical
:	O
a	O
case	O
series	O
.	O

Although	O
much	O
has	O
been	O
written	O
about	O
the	O
management	O
of	O
the	O
more	O
common	O
adverse	O
effects	O
of	O
lithium	B-Chemical
,	O
such	O
as	O
polyuria	B-Disease
and	O
tremor	B-Disease
,	O
more	O
subtle	O
lithium	B-Chemical
side	O
effects	O
such	O
as	O
cognitive	B-Disease
deficits	I-Disease
,	O
loss	B-Disease
of	I-Disease
creativity	I-Disease
,	O
and	O
functional	B-Disease
impairments	I-Disease
remain	O
understudied	O
.	O

RESULTS	O
:	O
We	O
report	O
seven	O
cases	O
where	O
substitution	O
of	O
lithium	B-Chemical
,	O
either	O
fully	O
or	O
partially	O
,	O
with	O
divalproex	B-Chemical
sodium	I-Chemical
was	O
extremely	O
helpful	O
in	O
reducing	O
the	O
cognitive,	B-Disease
motivational,	I-Disease
or	I-Disease
creative	I-Disease
deficits	I-Disease
attributed	O
to	O
lithium	B-Chemical
in	O
our	O
bipolar	B-Disease
patients	O
.	O

Treatment	O
of	O
previously	O
treated	O
metastatic	O
breast	B-Disease
cancer	I-Disease
by	O
mitoxantrone	B-Chemical
and	O
48	O
-	O
hour	O
continuous	O
infusion	O
of	O
high	O
-	O
dose	O
5-FU	B-Chemical
and	O
leucovorin	B-Chemical
(	O
MFL	B-Chemical
):	O
low	O
palliative	O
benefit	O
and	O
high	O
treatment	O
-	O
related	O
toxicity	B-Disease
.	O

Combination	O
chemotherapy	O
with	O
mitoxantrone	B-Chemical
,	O
high	O
-	O
dose	O
5-fluorouracil	B-Chemical
(	O
5-FU	B-Chemical
)	O
and	O
leucovorin	B-Chemical
(	O
MFL	B-Chemical
regimen	I-Chemical
)	O
had	O
been	O
reported	O
as	O
an	O
effective	O
and	O
well	O
tolerated	O
regimen	O
.	O

Median	O
number	O
of	O
courses	O
of	O
MFL	B-Chemical
regimen	I-Chemical
given	O
was	O
six	O
and	O
the	O
median	O
cumulative	O
dose	O
of	O
mitoxantrone	B-Chemical
was	O
68	O
.	O

Major	O
toxicities	B-Disease
were	O
cardiotoxicity	B-Disease
and	O
leukopenia	B-Disease
.	O

The	O
MFL	B-Chemical
regimen	I-Chemical
achieves	O
little	O
palliative	O
benefit	O
and	O
induces	O
severe	O
toxicity	B-Disease
at	O
a	O
fairly	O
high	O
rate	O
.	O

Administration	O
of	O
this	O
regimen	O
to	O
breast	B-Disease
cancer	I-Disease
patients	O
who	O
have	O
been	O
treated	O
by	O
chemotherapy	O
and	O
those	O
with	O
impaired	B-Disease
heart	I-Disease
function	I-Disease

The	O
expression	O
of	O
arginine	B-Chemical
vasopressin	I-Chemical
(	O
AVP	B-Chemical
)	O
gene	O
in	O
the	O
paraventricular	O
(	O
PVN	O
)	O
and	O
supraoptic	O
nuclei	O
(	O
SON	O
)	O
was	O
investigated	O
in	O
rats	O
with	O
lithium	B-Chemical
(	O
Li	B-Chemical
)-	O
induced	O
polyuria	B-Disease
,	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
and	O
radioimmunoassay	O
.	O

Plasma	O
sodium	B-Chemical
concentrations	O
were	O
found	O
to	O
be	O
slightly	O
increased	O
in	O
the	O
Li	B-Chemical
-	O
treated	O
rats	O
compared	O
with	O
those	O
in	O
controls	O
.	O

These	O
results	O
suggest	O
that	O
dehydration	B-Disease
and	O
/	O
or	O
the	O
activation	O
of	O
visceral	O
afferent	O
inputs	O
may	O
contribute	O
to	O
the	O
elevation	O
of	O
plasma	O
AVP	B-Chemical
and	O
the	O
upregulation	O
of	O
AVP	B-Chemical
gene	O
expression	O
in	O
the	O
PVN	O
and	O
the	O
SON	O
of	O
the	O
Li	B-Chemical
-	O
induced	O
diabetes	B-Disease
insipidus	I-Disease

The	O
serum	O
level	O
of	O
potassium	B-Chemical
was	O
observed	O
to	O
be	O
8	O
.	O

225	O
mg	O
,	O
for	O
correction	O
of	O
Dupuytren's	B-Disease
contracture	I-Disease
.	O

After	O
intravenous	O
administration	O
of	O
labetalol	B-Chemical
,	O
metoprolol	B-Chemical
and	O
midazolam	B-Chemical
the	O
patient	O
'	O
s	O
condition	O
improved	O
,	O
and	O
15	O
min	O
later	O
he	O
woke	O
up	O
.	O

Clinical	O
and	O
histopathologic	O
examination	O
of	O
renal	O
allografts	O
treated	O
with	O
tacrolimus	B-Chemical
(	O
FK506	B-Chemical
)	O
for	O
at	O
least	O
one	O
year	O
.	O

Memory	O
facilitation	O
and	O
stimulation	O
of	O
endogenous	O
nerve	O
growth	O
factor	O
synthesis	O
by	O
the	O
acetylcholine	B-Chemical
releaser	O
PG-9	B-Chemical
.	O

In	O
the	O
mouse	O
passive	O
-	O
avoidance	O
test	O
,	O
PG-9	B-Chemical
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
,	O
i	O
.	O

v	O
.)	O
was	O
also	O
able	O
to	O
prevent	O
antimuscarine	O
-	O
induced	O
amnesia	B-Disease
,	O
demonstrating	O
a	O
central	O
localization	O
of	O
the	O
activity	O
.	O

At	O
the	O
highest	O
effective	O
doses	O
,	O
PG-9	B-Chemical
did	O
not	O
produce	O
any	O
collateral	O
symptoms	O
as	O
revealed	O
by	O
the	O
Irwin	O
test	O
,	O
and	O
it	O
did	O
not	O
modify	O
spontaneous	O
motility	O
and	O
inspection	O
activity	O
,	O
as	O
revealed	O
by	O
the	O
hole	O
-	O
board	O
test	O
.	O

The	O
maximal	O
NGF	O
contents	O
obtained	O
by	O
PG-9	B-Chemical
were	O
17	O
.	O

The	O
current	O
work	O
indicates	O
the	O
ability	O
of	O
PG-9	B-Chemical
to	O
induce	O
beneficial	O
effects	O
on	O
cognitive	O
processes	O
and	O
stimulate	O
activity	O
of	O
NGF	O
synthesis	O
in	O
astroglial	O
cells	O
.	O

Accumulation	O
of	O
atracurium	B-Chemical
in	O
the	O
intravenous	O
line	O
led	O
to	O
recurarization	O
after	O
flushing	O
the	O
line	O
in	O
the	O
recovery	O
room	O
.	O

Circumstances	O
leading	O
to	O
this	O
event	O
and	O
the	O
mechanisms	O
enabling	O
a	O
neuromuscular	B-Disease
blockade	I-Disease

Over	O
the	O
period	O
1993	O
-	O
1996	O
,	O
551	O
cases	O
of	O
VTE	B-Disease
were	O
identified	O
in	O
Germany	O
and	O
the	O
UK	O
along	O
with	O
2066	O
controls	O
.	O

The	O
development	O
of	O
apomorphine	B-Chemical
-	O
induced	O
(	O
1	O
.	O

once	O
daily	O
)	O
aggressive	B-Disease
behavior	I-Disease
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
obtained	O
from	O
the	O
same	O
breeder	O
was	O
studied	O
in	O
two	O
consecutive	O
sets	O
.	O

Although	O
urinary	B-Disease
incontinence	I-Disease
is	O
listed	O
as	O
one	O
side	O
effect	O
of	O
these	O
drugs	O
in	O
their	O
package	O
inserts	O
there	O
is	O
only	O
one	O
report	O
in	O
the	O
literature	O
.	O

In	O
addition	O
to	O
their	O
effects	O
on	O
spasticity	B-Disease
,	O
certain	O
adverse	O
cardiorespiratory	O
effects	O
have	O
been	O
reported	O
.	O

BACKGROUND	O
:	O
An	O
association	O
has	O
been	O
found	O
between	O
transplant	B-Disease
glomerulopathy	I-Disease
(	O
TG	B-Disease
)	O
and	O
reduplication	O
of	O
peritubular	O
capillary	O
basement	O
membranes	O
(	O
PTCR	O
).	O
Although	O
such	O
an	O
association	O
is	O
of	O
practical	O
and	O
theoretical	O
importance	O
,	O
only	O
one	O
prospective	O
study	O
has	O
tried	O
to	O
confirm	O
it	O
.	O

RESULTS	O
:	O
We	O
found	O
PTCR	O
in	O
14	O
of	O
15	O
cases	O
of	O
TG	B-Disease
,	O
in	O
7	O
transplant	O
biopsy	O
specimens	O
without	O
TG	B-Disease
,	O
and	O
in	O
13	O
of	O
143	O
native	O
kidney	O
biopsy	O
specimens	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
in	O
transplants	O
,	O
there	O
is	O
a	O
strong	O
association	O
between	O
well	O
-	O
developed	O
PTCR	O
and	O
TG	B-Disease
,	O
while	O
the	O
significance	O
of	O
mild	O
PTCR	O
and	O
its	O
predictive	O
value	O
in	O
the	O
absence	O
of	O
TG	B-Disease
is	O
unclear	O
.	O

We	O
suggest	O
that	O
repeated	O
endothelial	B-Disease
injury	I-Disease
,	O
including	O
immunologic	B-Disease
injury	I-Disease

Conformationally	O
restricted	O
analogs	O
of	O
BD1008	B-Chemical
and	O
an	O
antisense	O
oligodeoxynucleotide	B-Chemical
targeting	O
sigma1	O
receptors	O
produce	O
anti	O
-	O
cocaine	B-Chemical
effects	O
in	O
mice	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	O
in	O
Swiss	O
Webster	O
mice	O
:	O
BD1018	B-Chemical
(	O
3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	B-Chemical
),	O
BD1063	B-Chemical
(	O
1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine	B-Chemical
),	O
and	O
LR132	B-Chemical
(	O
1R	O
,	O
2S	O
-(+)-	O
cis	O
-	O
N	O
-[	O
2	O
-(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]-	O
2	O
-(	O
1	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
).	O
Competition	O
binding	O
assays	O
demonstrated	O
that	O
all	O
three	O
compounds	O
have	O
high	O
affinities	O
for	O
sigma1	O
receptors	O
.	O

Moreover	O
,	O
post	O
-	O
treatment	O
with	O
LR132	B-Chemical
prevented	O
cocaine	B-Chemical
-	O
induced	O
lethality	O
in	O
a	O
significant	O
proportion	O
of	O
animals	O
.	O

Together	O
,	O
the	O
data	O
suggests	O
that	O
functional	O
antagonism	O
of	O
sigma	O
receptors	O
is	O
capable	O
of	O
attenuating	O
a	O
number	O
of	O
cocaine	B-Chemical

terfenadine	B-Chemical
and	O
terodiline	B-Chemical
).	O
2	O
.	O

The	O
potential	O
of	O
compounds	O
to	O
cause	O
TDP	B-Disease
was	O
evaluated	O
by	O
monitoring	O
their	O
effects	O
on	O
MAPD	O
in	O
dog	O
.	O

9	O
nM	O
),	O
terodiline	B-Chemical
(	O
76	O
nM	O
),	O
cisapride	B-Chemical
(	O
11	O
nM	O
)	O
and	O
E4031	B-Chemical
(	O
1	O
.	O

Clinically	O
,	O
the	O
onset	O
was	O
characterized	O
by	O
the	O
signs	O
of	O
opistothonus,	B-Disease
sensory	I-Disease
and	I-Disease
motor	I-Disease
dysfunction	I-Disease
and	O
ascending	O
paralysis	B-Disease
.	O

A	O
better	O
controlled	O
regimen	O
for	O
administering	O
vincristine	B-Chemical

The	O
intensity	O
of	O
headache	B-Disease
and	O
nausea	B-Disease
was	O
measured	O
with	O
a	O
100	O
-	O
mm	O
visual	O
analog	O
scale	O
.	O

Thus	O
,	O
the	O
relationship	O
between	O
cholinergic	O
activity	O
and	O
responsiveness	O
and	O
alcohol	B-Chemical
withdrawal	O
was	O
investigated	O
in	O
a	O
genetic	O
animal	O
model	O
of	O
ethanol	B-Chemical
withdrawal	O
severity	O
.	O

Potassium	B-Chemical
was	O
applied	O
by	O
reverse	O
dialysis	O
twice	O
,	O
separated	O
by	O
75	O
min	O
.	O

However	O
,	O
the	O
increase	O
in	O
release	O
of	O
ACh	B-Chemical
produced	O
by	O
the	O
first	O
application	O
of	O
KCl	B-Chemical
was	O
2	O
-	O
fold	O
higher	O
in	O
WSP	O
versus	O
WSR	O
mice	O
.	O

Six	O
-	O
to	O
9	O
-	O
month	O
old	O
rats	O
receiving	O
prenatal	O
dexamethasone	B-Chemical
on	O
days	O
17	O
and	O
18	O
of	O
gestation	O
had	O
a	O
17	O
%	O
reduction	O
in	O
glomeruli	O
(	O
23	O
380	O
+/-	O
587	O
)	O
compared	O
with	O
control	O
rats	O
(	O
P	O
<	O
0	O
.	O

08	O
)	O
for	O
CPA	B-Chemical
/	O
EE	B-Chemical
use	O
compared	O
with	O
an	O
OR	O
(	O
adj	O
)	O
of	O
2	O
.	O

Risks	O
of	O
the	O
consumption	O
of	O
beverages	O
containing	O
quinine	B-Chemical
.	O

The	O
protective	O
action	O
of	O
subcutaneously	O
(	O
SC	O
)	O
administered	O
antidotes	O
or	O
their	O
combinations	O
in	O
DFP	B-Chemical
(	O
2	O
.	O

0	O
mg	O
/	O
kg	O
BW	O
),	O
anticonvulsant	O
diazepam	B-Chemical
(	O
2	O
.	O

